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The mucosal barrier in the intestine is vital to maintain selective absorption of 
nutrients while protecting internal tissues and maintaining symbiotic relationship with 
luminal microbiota. This bio-barrier consists of a cellular epithelial barrier and an acellular 
mucus barrier. Secreted mucus regulates barrier function via in situ biochemical and 
biophysical interaction with luminal content that continually evolves during digestion and 
absorption. Increasing evidence suggests that a mucus barrier is indispensable to maintain 
dynamic homeostasis of the gastrointestinal tract. However, the importance of mucus 
barrier has been largely underrated for in vitro mucosal tissue modeling. The major gap is 
the lack of experimental material (i.e. functional mucins) and platforms to integrate a 
relevant thickness of mucus layer with an epithelium under physiological conditions.  
Here we report our progress on developing human-relevant models of the mucosal 
barrier in physiological settings by using natural mucins derived from a porcine small 
intestine (PSI). To overcome limited availability of functional mucus, we first developed a 
simple and scalable protocol for natural mucus extraction by directly solubilizing a 
 
vii 
relatively sterile inner mucus layer from PSI that is readily accessible. Subsequently, 
functional separation of mucin proteins was performed by exploiting pH-dependent 
reversible sol-gel transition. Under optimized alkaline condition (0.01M NaOH), the 
mucus layer was selectively solubilized from the mucosal surface with a 72% yield (1275 
mg/m PSI). The extracted and purified natural mucins retained essential biophysical and 
biochemical characteristics. The in vitro mucus barrier model enabled us to discover ionic 
(Ca2+) environment dependent mucus barrier and its transport properties.  
The mucus barrier was successfully integrated with human epithelial cell layer (HT-
29), which allowed the studies of bi-directional crosstalk between luminal content and 
tissue immune cells through a physiologically relevant mucosal interface. The applied 
mucus barrier did not cause any cytotoxic or immunogenic effects to human intestinal and 
immune cells. As expected, mucus prevents the transmigration of probiotic bacteria 
VSL#3. In the absence of mucus, these bacteria caused epithelial damage, immune cell 
differentiation and induced production of pro-inflammatory cytokines IL-8 and TNF-α. 
The most intriguing result from these studies was that mucus increased the transmigration 
of pathogenic Salmonella. Similar to the transmigration of probiotic bacteria, breach of the 
mucosal barrier by Salmonella induced production of IL-8 and TNF-α. The importance of 
bacterial motility was confirmed by showing that Salmonella with a knockout that prevents 
flagella formation does not penetrate the barrier. Co-cultures of VSL#3 and Salmonella in 
the mucosal barrier platform demonstrated the differences in epithelial and immune cell 
responses under symbiosis or dysbiosis like conditions. 
Taking bioengineering approaches, we have developed mucosal barrier models of 
intestines. Established models represent cellular and extracellular complexities in a 
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controlled and accessible manner. We envision that in vitro mucosal barrier models will 
serve as an enabling tool for understanding basic biology and disease progression in the 
intestines. Technologies, methods, and protocols developed here lay the foundation for 
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The gastro-intestinal tract (GIT) performs essential functions in the human body. GIT is 
responsible for the processing and digestion of food and absorption of essential nutrients 
for survival. Apart from nutrient absorption, GIT maintains physiological homeostasis by 
protecting the internal tissue from persistent chemical, physical, and microbial insults while 
facilitating passage of desired molecules 1-3. GIT is the largest reservoir of bacteria in the 
body with bacterial density as high as 1012 cfu/g 4 and houses almost 70% of the immune 
system in the form of gut-associated lymphoid tissue (GALT) 5. The mucosal barrier along 
the luminal side of GIT is essential for protection against the harsh luminal environment 
along with development of the host immunity 6. This bio-barrier is composed of a cellular 
epithelial barrier and an acellular mucus barrier. Acellular mucus barrier is the first line of 
defense and physically separates the acid and digestive enzymes in the stomach and small 
intestines, and dense bacterial population in the large intestines from underlying tissue.  
 
The GIT mucosal barrier is unique due to its strategically modified anatomical structure, 
cellular composition, mucus layer thickness and complex biochemical milieu. These 
features are key to maintain the balance between absorption and protection from the 
luminal compartment 7-9. The structural and environmental complexity, difficulty to access 
the GIT, and dissimilar microbiota population have limited the use of live animal models 
for studying dynamic interaction of mucosal barrier with luminal components that affect 
the barrier function 10. As a consequence, great progress has been made to recreate 
intestinal cellular physiology 11, three-dimensional (3D) morphology 12-13, mechanically 
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active environment 14, and microenvironment compatible for host-microbe interactions 12, 
15-17 in vitro. The in vitro systems allow the study of fundamental interactions between 
different cell types of the intestine by eliminating biological complexity inherently present 
in the tissue in vivo. In vitro functional human mucosal barrier models serve as an enabling 
tool for understanding basic biology and disease progression in the gastrointestinal tract. 
Recently, these models are becoming invaluable pre-clinical testing platforms for orally 
administrated drug compounds and probiotics since they provide an effective, low cost and 
high throughput way to gain useful information before performing cost-intensive animal 
and human trials. 
 
Intestinal epithelium is a monolayer of cells that are highly polarized and consist of the 
absorptive enterocytes and the secretory goblet cells as major cell populations. In vitro, 
Caco-2 cells are the most commonly used model system for mimicking the epithelium as 
they spontaneously differentiate into mature enterocytes in culture that express 
morphological features such as the brush border expression, tight junctions and surface 
microvilli 18 that are similar to small intestine in vivo 19. HT-29 colon adenocarcinoma cells 
cultured in medium without glucose also undergo enterocytic differentiation 20. Further 
advancement in this field was achieved by treating HT29 cell line with chemotherapeutic 
drugs methotrexate and 5-fluorouracil. Treatment with these drugs caused differentiation 
of HT29 cells into a goblet cell phenotype and with further selection stable mucus 
producing cell lines HT29-MTX and HT29-FU were established 21-22.  Co-culture of Caco-
2 and HT29-MTX cells at different cell ratios was shown to represent the in vivo like cell 
population of the intestines. For example, a ratio of (9:1) Caco-2:HT-29 MTX closely 
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matched the Caco-2 monocultures that best represent the small intestinal cell population 23. 
Extracellular matrix proteins like collagen, gelatin and Matrigel are used to recreate the 
basement membrane that provides attachment sites and support for the epithelial cell 
growth. Furthermore, these provide stimulation for epithelial cell expansion, spreading, 
and differentiation 24. 
 
For drug/nutrient absorption and transport studies, epithelial cells are seeded onto 
permeable membrane supports made of polycarbonate and allowed to cover the entire 
membrane as a monolayer 25. These membrane supports known as transwell inserts fit 
inside commonly used multi-well plates and create the apical and basolateral compartments 
mimicking the luminal as well as the basal sections of the intestinal tissues. Caco-2 cell 
monolayers in transwell inserts are the most commonly used model for drug transport 
across intestinal epithelium 26. These monolayers have been heavily used by researchers to 
mechanistically study transport of drugs, nutrients, etc. Caco-2 and Raji B cell co-culture 
was used for M-cell like differentiation in transwells by normal 27 and inverted 28 
configurations. M-cell like differentiation was used to study the process of transcytosis 
across the monolayer which is commonly observed in the small intestine and important for 
development of immunity. Finally, to incorporate a mucus layer in this model a triple co-
culture of Caco-2, HT29-MTX and Raji B was used 29 
 
Mucosal interfaces are a major target for drug delivery and mucus layer is the first barrier 
that a free drug or a drug delivery vehicle must overcome before reaching the cell surface 
30-31. Although there have been successful efforts in stimulating the cultured epithelial cell 
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lines to secrete mucus, the amount of mucus secreted is very small compared to in vivo. In 
most cases mucus is observed in patches and does not fully cover the surface of epithelial 
cell layer. Also, due to high variability in the culture conditions and the amount of mucus 
produced under different culture conditions, researchers have applied mucus extracted 
from excised tissues to cultured cell layers on transwell membranes 32. This approach 
provides multiple benefits over mucus secreting cell lines. A uniform layer of mucus can 
be applied while most mucus secreting cell layers form non-uniform or patchy mucus layer. 
The thickness of the mucus layer can be controlled precisely, whereas thickness control is 
not feasible with the mucus secreting cell layers. The composition and the concentration of 
mucus can be defined according to the organ system being mimicked. Experimental 
variations can be reduced by pooling large quantities of extracted mucus or using 
commercially available mucins. However, a few drawbacks of this approach are limited 
availability of human derived tissues and therefore use of animal derived mucus and 
potential cytotoxic effects of animal derived mucus on human cells.  
 
Mucins are available commercially from different organs of animals but have been shown 
to have significantly degraded properties compared to native mucus that may cause the 
results of the studies to deviate from in vivo 33. Obtaining highly purified mucins require 
very sophisticated and expensive instrumentation and expertise, therefore, due to easy 
accessibility commercial mucins are used frequently in research studies. For example, an 
artificial intestinal mucus was developed using commercially available porcine gastric 
mucin and the rheological properties were matched with native pig intestinal mucus. 
Further optimization was carried out to reduce cell death and have no effect on the barrier 
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integrity of the Caco-2 cell monolayer 34. The artificial mucus was applied to Caco-2 cell 
monolayer in a transwell platform and permeability of hydrophilic (mannitol, FD4, FD10 
and fluorescein isothiocyanate-bovine serum albumin) and hydrophobic (testosterone) 
compounds was tested. Biosimilar mucus present on the epithelial cell layers acted as a 
barrier to hydrophobic compounds and introduced a lag time for the diffusion of 
hydrophilic compounds. Biosimilar mucus also showed more consistent results for creating 
a steric barrier in comparison to native porcine intestinal mucus validating this approach to 
model mucus barrier in vitro 35. 
 
Three-dimensional cell cultures have been demonstrated to mimic organ physiology better 
than traditional two-dimensional culture 36. Three-dimensional models of the intestine are 
enabled recently by the development of microfabrication techniques like photolithography, 
microcontact printing, and replica molding. These techniques have been coupled with 
biomaterials that mimic the basement membrane of the intestinal tissue. 3D villous like 
geometries have been created using collagen 31, 37, silicon 38, and poly lactic-glycolic acid 
(PLGA) 39. These studies demonstrated that Caco-2 epithelial cell differentiation and 
polarization is dependent on the location along the villous like structures which mimic the 
in vivo conditions. The researchers further tested the application of these models for 
evaluation of probiotics Lactobacillus gasseri and E. coli Nissle 1917 in preventing 
adhesion of pathogenic bacteria Salmonella typhimurium and Pseudomonas aeruginosa 40. 
The model enabled the dissection of mechanisms by which different probiotic bacteria 
exert their probiotic effect in a physiologically relevant environment. 
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Tubular constructs have been created using silk biomaterial that closely mimic the tubular 
structure of intestines by including three-dimensional folds on the luminal side of the 
constructs 12. The silk scaffolds were seeded with human myofibroblasts within the bulk 
of the scaffold to add the mesenchymal cell component to support the epithelial cell growth 
in the lumen of the model. Caco-2 and HT29-MTX were co-cultured in the lumen of the 
scaffold. The tubular design and the three-dimensional luminal structure of the scaffold 
enabled the luminal oxygen tensions to stay in the anaerobic zone for long term. Long term 
(approx. 8 weeks) survival, mucus production and functional maintenance of cells in the 
silk scaffolds provided great advantages for chronic studies alongside co-culture of live 
anaerobic bacteria with epithelial cells. The system was utilized to study parasite-epithelial 
cell interactions using Cryptosporidium parvum as a model organism 41. The diarrhea 
causing C. parvum successfully infected the model for 17 days and was serially transferred 
to three new scaffolds to re-establish infection. 3D silk scaffolds were also used to study 
toxic effects of Clostridioides difficile post germination and colonization 42. Toxigenic C. 
difficile was significantly more toxic and caused higher epithelial cell death in the 3D 
model compared to 2D transwells. 
 
A major advance was achieved in the field of in vitro intestine modeling with the 
development of ‘gut-on-a-chip’ platform. The microfluidic platform is made of 
polydimethylsiloxane (PDMS) with two microfluidic channels separated by a thin porous 
PDMS membrane. The porous PDMS membrane coated with Matrigel supported epithelial 
cell growth on the apical side and endothelial cells on the basolateral side. The apical and 
basolateral channels incorporated flows to mimic the luminal and vascular flow conditions. 
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Alongside flow, the system induced cyclic stretching of the PDMS membrane using a 
pneumatic system and the epithelial cells were subjected to in vivo like peristalsis. 
Epithelial (Caco-2) cells differentiated and polarized into villous like structures within 3 
days compared to 3 weeks in transwell culture 11, 14. The system enabled co-culture of live 
bacteria in the apical channel for more than 1 week without compromising epithelial cell 
viability and was further used as a model for inflammatory conditions in the intestines 15. 
This was achieved by culturing vascular endothelial cells on the basolateral side of the 
PDMS membrane and flowing immune cells in the basolateral channel. By stopping the 
membrane stretching, the system successfully captured bacterial overgrowth on the 
epithelial cell layer leading to higher pro-inflammatory cytokine secretion and immune cell 
infiltration. This system has been recently adapted to incorporate biopsy derived stem cell 
organoids and induced pluripotent stem cell derived organoids that form the epithelial 
layer, therefore, demonstrating the ability to create personalized intestinal model 43-44.  
 
Current in vitro models of intestines can be broadly classified as static and dynamic models. 
Static models such as transwell platforms and biomaterial scaffolds are commonly used for 
molecular and drug diffusion or absorption studies. These models do not provide the 
mechanically active environment that the cells experience in vivo. Also, static models are 
not suitable for performing host-microbial co-cultures due to lack of mucus, flow, and 
bacterial overgrowth. On the other hand, dynamic models can simulate in vivo like 
mechanical forces by incorporating fluid flow and stretching. Under these conditions long-
term co-culture of bacteria with human epithelial and immune cells has been demonstrated 
either in the absence of mucus or using commercial porcine gastric mucin (PGM).  
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Despite significant progress in creating in vitro models of intestinal tissue with higher 
complexity there are few challenges that remain unmet. 
• In vivo, a mucus layer tightly bound to epithelial cells physically separate bacteria 
from coming in contact with the epithelial cells and communication occurs via 
bacterial metabolites or host derived factors that diffuse across the mucus layer. 
Such selective barrier function has been challenging to demonstrate in vitro.   
• Mucus secreting cell layers secrete very small amount of mucus compared to in 
vivo tissues. Mucus layer thickness is an important mechanism for separating 
bacteria and other luminal components that cause inflammation. The ability to 
recapitulate this phenomenon in vitro will significantly improve physiological 
significance of the in vitro mucosal barrier models. 
• Commercially available mucus fails to recapitulate the properties of mucus due to 
enzymatic degradation and current mucus purification methods require extensive 
instrumentation producing low quantities of mucus. Therefore, development of 
methods for extraction of mucus that have intact functional properties will advance 
the engineering of intestinal mucosa models. 
Taking into consideration the recent progress in the development of engineered intestinal 
models, current work aims to develop the basic technical strategies and platforms to 






DEVELOPMENT OF A SCALABLE METHOD FOR MUCUS EXTRACTION 
AND IN VITRO RECONSTITUTION OF AN INTESTINAL MUCUS LAYER 
 
2.1 Introduction 
The role of mucus in the intestines is incompletely understood. The mucus layer functions 
as a selective biological barrier that permits transport of digested molecules while 
protecting the underlying epithelial tissue1-3. The content in the lumen is continually 
changing and the mucus layer must respond to its environment by being a barrier to some 
components while being permeable to others2. The rheology and microscopic structure of 
mucus affects its ability to prevent bacterial infiltration45-46. Many diseases involve 
dysfunction of the mucus barrier, such as inflammatory bowel diseases47-49, cystic 
fibrosis50, and colorectal cancer51-52. In diseased states, breakdown of the mucus 
microstructure increases bacterial infection53-54. Two factors that have been shown to affect 
these structural properties are the local pH and cation content55. An experimental model 
that can expand the understanding of these mechanisms would be an essential tool to 
address diseases of the intestines.  
 
The mesh-like structure of the mucus barrier enables it to promote nutrient absorption while 
acting as a barrier to infection. Mucus is primarily made up of mucin proteins. In both the 
large and small intestine, mucus is composed predominantly of MUC2, one of the 21 
known proteins in the MUC family56-57. In the small intestine, where most nutrient 
absorption occurs, the mucus barrier is thin (20-100 µm thick), which facilitates molecular 
transport while maintaining tissue sterility against luminal microbes58-59. In the large 
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intestine, the mucus barrier is thicker (700-1,000 µm), which physically shields the 
epithelial lining from the high density of the microbiota60-62. In the large intestine, the 
mucus layer is composed of a tightly bound inner layer and a loosely bound outer layer63. 
Secreted mucus traps invading bacteria which are eliminated with the luminal content64-65. 
 
The local environment around the mucus layer greatly affects its structural properties. The 
most well studied environmental factor is pH, which has a strong effect on the rheology of 
mucus66-67. In acidic environments, mucus is elastic and gel-like, but in neutral and basic 
environments, it behaves more like a liquid solution66. Mucin proteins have a bottlebrush-
like structure with a protein backbone and glycan side chains68 (Figure 2.1A). At acidic pH 
values, mucins change conformation and expose cysteine-rich hydrophobic regions on the 
protein backbone, which leads to hydrophobic interactions and gelation69-70. In addition to 
pH, other factors may affect the structure of mucus71. Calcium ions (Ca2+) plays an 
important role in regulating intracellular mucin storage and secretion from goblet cells55, 
72. The binding of Ca2+ with the glycan side chains causes dense packing of the mucin 
polymeric chains55, 73-74. In the intestines, where the luminal pH is neutral75, dietary calcium 
may have a greater effect on mucus structure and its barrier function. After ingesting food, 
the availability of calcium and other ionic molecules in the gastro-intestinal tract is 
increased76-77. Depending on the fed state, the luminal Ca2+ concentration varies between 
5-20 mM76, 78.  
 
Much of current in vitro research has used mucus extracted from the stomach79-80. It is 
plentiful, less contaminated with bacterial components, and its extraction is 
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straightforward. This material has been instrumental in demonstrating its pH dependent 
behavior and barrier function67, 70, 81-83. Commercially available gastro-intestinal mucus is 
derived from porcine stomachs. A limitation of this material is that gastric mucins have a 
different biochemical structure from intestinal mucins. Gastric mucus is mostly MUC5AC 
and MUC684, whereas the intestines is primarily MUC256. In addition, commercial mucin 
has poor gel-forming capability85. This transition is an essential aspect of the primary 
barrier function of mucus. 
 
In the absence of a commercial source, there are two predominant methods used to study 
intestinal mucus derived from rodent, large animal, or human tissues. The most common 
is direct scraping of mucus from the wall of intestines. Scraped mucus has been used to 
demonstrate that large nanoparticles, if properly coated, can rapidly penetrate mucus 
compared to smaller nanoparticles86. It has also been shown that the interaction of mucus 
with food associated stimuli such as lipids, calcium and pH significantly reduce the 
transport of microspheres76. An important limitation of this scraping technique is that 
contamination of unprocessed mucus with cellular debris can cause unwanted 
immunological responses or cytotoxicity in vitro34. Alternatively, several studies have 
purified the mucin proteins from intestinal mucus87-88. Purified mucins retain the 
rheological properties of mucus89-90 and have been used to show that mucin chain 
entanglement is dominant at neutral pH and high concentration91. At low pH the gel 
formation is accompanied by formation of large‐scale heterogeneities within the mucin 
solutions92. This purification method has limited yield, is time intensive and requires costly 
specialized equipment, which limits its widespread use for effective recapitulation of 
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mucus barriers with physiological thickness and concentration in vitro. In recent years, 
little progress has been made in advancing mucus extraction protocols at large scale90, 93-
94. 
 
The goal of our study was to develop a method for extracting intestinal mucus and to 
quantify the effect of environmental factors on its barrier properties. We hypothesized that 
the permeability and barrier function of intestinal mucus is reversible and changes in 
response to calcium ions in the local environment. To quantify these properties, the 
extraction method needed to produce sufficient quantities of mucus that retained its pH-
responsive rheology and contained minimal cellular contaminants. A systematic process 
was used to determine the extraction conditions that would result in a high yield, cause 
minimal cellular damage, and isolate mucus that would form a gel. Spectrometric and 
rheometric measurements were used to quantify the absorbance and physical properties in 
response to acidic and high calcium environments. The physical structure of mucus 
proteins in these environments was determined by microscopy. The ability of mucus to 
limit molecular diffusion and bacterial penetration was determined in an in vitro mucus 
barrier model. This development of a high throughput extraction method will enhance 
mucus research. Understanding the mechanisms that control the barrier function of mucus 





2.2.1. Extraction of Natural Mucus  
We have developed a new method to extract mucus from the porcine small intestines 
(Figure 2.1B). The goal of the design process was to develop a method that isolates mucus 
while retaining its pH-responsive rheology and minimizing the inclusion of cellular 
contaminants. This method was based on the observation that after mucus is scraped from 
the intestine, it dissolves in an alkaline solution. To determine the optimal solution to 
dissolve mucus from the intestine in situ, washed intestinal tubules were filled with 1M 
HCl, PBS or 1 M NaOH for 24 hours (Figure 2.1C). Before treatment, the intestinal lining 
was undamaged, and mucus was tightly bound to the lining (Figure 2.1C, left). The pH of 
the solvating solution affected the appearance of the intestine and the mucus layer (Figure 
2.1C&D) and extent of solvation (Figure 2.1E). Filling the intestinal tubules with an acidic 
solution (1 M HCl) for 24 hours turned the mucus layer into a whitish gel and the tissue 
became rigid (Figure 2.1D, middle left). A neutral solution (saline) only partially 
solubilized the mucus layer (Figure 2.1D, middle right). An alkaline solution (1 M NaOH) 
dissolved most of the mucus layer and turned the viscera semi-solid (Figure 2.1D, right). 
The total amount of protein in the alkaline solution was significantly higher (P<0.05) than 
in the HCl and PBS solutions (Figure 2.1E).  
 
The concentration of the alkaline solution affected the amount of protein recovery and the 
extent of tissue damage (Figure 2.1F-H). Treatment with HCl (Figure 2.1F, middle left) 
caused some tissue damage compared to untreated controls (Figure 2.1F, left). Treatment 
with PBS did not significantly affect the epithelial tissue, which retained much of the 
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villous architecture of untreated tissue (Figure 2.1F, middle right and inset). At a strength 
of 1 M NaOH, the underlying epithelial tissue showed some damage and individual villi 
were difficult to identify (Figure 2.1F, right). Treatment with a lower concentration of 
NaOH (0.01 M), compared to 1M NaOH, reduced epithelial damage and retained villous 
architecture (Figure 2.1G). Treatment with 0.1 M NaOH, produced comparable amounts 
of recovered protein to treatment with 1 M NaOH (Figure 2.1H). The amount of recovered 
protein significantly decreased after treatment with NaOH solutions of lower concentration 
(0.01 M and below; P < 0.05; Figure 2.1H). 
 
The amount of cellular contaminant proteins in the extracted mucus was reduced by 
exploiting the reversible, pH-dependent sol-gel transition of mucin (Figure 2.1I). After 
intestinal mucus was solubilized in 0.01 M NaOH, it was purified by a pH adjustment step. 
The acidity of the solution was reduced to a pH of 4.0 and then increased to a value of 8.0. 
When the pH was reduced, a gel formed (Figure 2.1B) enabling the supernatant to be 
removed. One cycle of this pH-adjustment process reduced the total protein in the extract 
by 40% (P < 0.05), but repeated sol-gel cycles did not significantly change the protein 
content (Figure 2.1I). It took 4 sol-gel cycles to reduce the DNA content by 30% (P < 0.05; 
Figure 2.1J). DNA contamination was reduced significantly by DNase treatment (P < 0.05; 
Figure 2.S1). The removed supernatant did not gel at pH 4.0. After dialysis and 
lyophilization, the entire process generated 1,274 ± 49 mg of dry protein per meter of 
intestine. The theoretical amount of mucus in the intestine was calculated to be 1,775 
mg/m, accounting for the increase in cross-sectional surface area due to plicae circularis 
and villi structure (Figure 2.S2) (95-96). Compared to this theoretical value, PSIM extraction 
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had a yield of 71.75 %. The final product reconstituted in a buffer medium was termed 
porcine small intestinal mucus (PSIM).  
 
2.2.2 Reconstituted PSIM Preserves Reversible pH Dependence. 
The pH of PSIM affected its appearance, absorbance, rheological properties, and 
aggregation. At pH 7, reconstituted PSIM (20 mg/ml) was optically clear and became 
turbid at lower pH (Figure 2.2A, left and middle). High concentration PSIM (80 mg/ml) 
was a viscous fluid that flowed in an inverted tube (Figure 2.2B left tube). At pH 4, high 
concentration PSIM formed a gel that retains its shape in an inverted tube (Figure 2B right 
tube). The turbidity of reconstituted PSIM increased with decreasing pH until a maximum 
at pH 4 (Figure 2.2C top). This change in physical appearance matched the absorbance at 
410 nm over this range (Figure 2.2C bottom). Reconstituted PSIM exhibited an absorbance 
peak at 410 nm in the range from 290 to 790 nm (Figure 2.S3). The absorbance at pH 4 
was significantly greater than at pH 7 (P < 0.05) and pH 2 (P < 0.05; Figure 2.2D) and the 
greatest difference in absorbance was between pH 7 and pH 6 (P < 0.05).  
 
The rheological properties of reconstituted PSIM matched the physical appearance and 
absorbance.  The viscous (G՛՛) and elastic (G՛) moduli were greater at pH 4 than at pH 7 (P 
< 0.05; Figure 2.2D), matching the gel-like behavior at low pH (Figure 2.2B). Further 
acidification to pH 2, reduced both moduli from that of pH 4 (P < 0.05; Figure 2.2D) similar 
to the reduction in absorbance (Figure 2.2C). For all pH levels (2, 4, and 7), G՛ was greater 
than G՛՛ (P < 0.05), and the greatest difference (more than 4 times) was at pH 4 (Figure 
2D). The elastic modulus was greater than the viscous modulus over the entire frequency 
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range from 1 to 68.3 rad/s (Figure 2.S4). At a microscopic level, pH affected the 
aggregation of PSIM (Figure 2.2E). At pH 7 no aggregation was observed. At pH 6 and 
below, microscopic aggregates were present (Figure 2.2E). The overall size and branching 
of PSIM aggregates gradually increased with decreasing pH until a pH value of 4. At pH 
values of 3 and lower, the size of the aggregates decreased. Area coverage increased with 
decreasing pH until a value of 4 and then decreased as pH was reduced to a value of 2 
(Figure 2.2F). The pH affected the physical properties of PSIM similarly. Each had its 
highest value at pH 4. Absorbance correlated positively with the viscous modulus (R2 = 
0.95), the elastic modulus (R2 = 0.90) and the area coverage (R2 = 0.9998).  
 
The pH-dependent change in absorbance was reversible. As the pH of a PSIM solution was 
rapidly changed from 8 to 4 and back to 8 (Figure 2.2G) the solution went from clear to 
turbid and back to clear (Figure 2.2A). When this reversibility was quantified using 
absorbance measurements and smaller pH intervals, the results matched the observed 
changes in turbidity. Decreasing the pH of the PSIM solution from 8 to 4 increased 
absorbance and it returned to a similar value as the pH was increased back to 8 (Figure 
2.2G). 
 
2.2.3 Barrier Function of PSIM is pH Dependent 
The mucus barrier function changed with the pH and aggregation of PSIM. When a 
bacterial solution was applied to a transwell membrane covered in PSIM, transmigration 
of the bacteria resulted in an increase in bacterial density in the bottom well as a function 
of time (Figure 2.3A-B). Two species of bacteria, Escherichia coli (Figure 2.3A) and 
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Salmonella enterica serovar Typhimurium (Figure 2.3B), both transmigrated through 
mucus. PSIM at pH 7, which had not formed a gel, significantly slowed E. coli 
transmigration compared to a PSIM-free control (P < 0.05; Figure 2.3C). Salmonella 
transmigration was not affected by the presence of PSIM at pH 7 (Figure 2.3B). At pH 4, 
the aggregated PSIM significantly decreased transmigration of both bacteria (P < 0.05). At 
pH 2, bacterial transmigration was significantly reduced compared to pH 7, while more 
bacteria migrated across the mucus barrier compared to pH 4 (P < 0.05). These effects on 
bacterial transmigration were significant at all time points (Figure 3A-B) and were 
inversely correlated with PSIM aggregation (R2 = -0.97 for E. coli and R2 = -0.99 for 
Salmonella; compare Figure 2.3C-D to 2F).  
 
PSIM affected the motility of both Salmonella and E. coli at low pH (Figure 2.3E-H). In 
PSIM at pH 7, the average speeds of E. coli and Salmonella were not different from PSIM-
free controls (Figure 2.3F).  At pH 4, aggregated PSIM significantly decreased the motility 
of both species; the speeds of E. coli and Salmonella were slowed by 370% and 40% 
compared to controls (P < 0.05, Figure 2.3F). In PSIM at pH 7, both bacterial species were 
in a free-swimming state. In both aqueous controls and neutral pH PSIM, more than 80% 
of the bacteria were motile with speeds of at least 2 µm/s (Figure 2.3G-H). In aggregated 
PSIM at pH 4, the bacteria were immobilized. At pH 4, the presence of PSIM increased 
the percentage of non-motile Salmonella and E. coli with speeds less than 2 µm/s from 
35% to 54% and 12% to 87%, respectively (P < 0.05).  Salmonella were more motile than 
E. coli in PSIM at pH 4; there were fewer immobilized bacteria (speed < 2 µm/s; P < 0.05) 
and more moderately motile bacteria (speed = 2 to 4 µm/s; P<0.05). The effect of pH on 
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motility indicates how pH affected bacterial migration through layers of PSIM (Figure 
2.3A-D). 
 
2.2.4 Calcium Regulates PSIM at Neutral pH. 
Calcium affected the microscopic and macroscopic properties of PSIM. The addition of 
calcium at neutral pH increased the visible turbidity and absorbance of PSIM in a similar 
manner to reducing pH (Figure 2.4). At pH 7, PSIM was optically clear. Increasing the 
Ca2+ concentration proportionally increased the turbidity (Figure 2.4A). At pH 4, 
increasing the Ca2+ concentration had no effect on the turbidity of PSIM. Similar to pH, 
absorbance at 410 nm matched turbidity. At pH 7, increasing the Ca2+ concentration 
significantly increased PSIM absorbance (P < 0.05), whereas, at pH 4, increasing the Ca2+ 
concentration did not affect the absorbance (Figure 2.4B). The effect of calcium on 
absorbance was reversible. Addition of calcium chelating EDTA reduced the absorbance 
that increased in response to the addition of calcium (P < 0.05; Figure 2.4C).   
 
Calcium caused similar microscopic changes to PSIM as acidic pH. Small aggregates 
formed at pH 7 with 1 mM Ca2+ (Figure 2.4D), whereas no aggregates formed without Ca2+ 
(Figure 2.2E). With 1 mM Ca2+, area coverage increased with pH until a value of 4 and 
then decreased (Figure 2.4E) with a similar pattern to PSIM without calcium (Figure 2.2F). 
The effect of calcium was greatest at neutral pH. The addition of 1 mM Ca2+ significantly 
increased (P < 0.05) the area coverage (Figure 2.4E) compared to PSIM without calcium 




2.2.5. Calcium Controls the Thickness and Porosity of the Mucus Barrier.  
At neutral pH, the Ca2+ concentration affected the thickness and permeability of PSIM. 
When the Ca2+ concentration was 5 mM and above, PSIM formed visible layers after 
overnight incubation as aggregated mucins precipitated (arrows in Figure 2.5A). No layers 
formed when the Ca2+ concentration was 1 mM. The thicknesses of the mucus layers 
increased linearly with Ca2+ concentration (P < 0.05; Figure 2.5B). The mucus layers 
formed at different Ca2+ concentrations affected the transport of fluorescent FITC-dextran 
in an unexpected manner (Figure 2.5C-D); the lowest transport was not observed in the 
thickest layer. The FITC-dextran concentration, which resulted from diffusion through 
PSIM layers, increased with time (Figure 2.5C). FITC-dextran transport was highest at 1 
mM Ca2+, where there was no visible PSIM barrier (P < 0.05; Figure 2.5D). Transport was 
lowest at 5 mM Ca2+ (P < 0.05). At Ca2+ concentrations of 10 and 20 mM, the transport of 
FITC-dextran was greater than at 5 mM, even though the barriers were thicker (P < 0.05; 
Figure 2.5D). This pattern was consistent for all time points (Figure 2.5C).  
 
The differences in diffusion for the PSIM layers formed with different levels of Ca2+ was 
caused by its microscopic structure. Calcium affected the size of PSIM aggregates, the 
spacing between them and the total area of aggregated material. In the presence of 1 mM 
Ca2+, PSIM formed microscopic, 2-5 µm diameter aggregates (Figure 2.6A). In 5 mM Ca2+ 
there were more aggregates of about the same size. At 10 and 20 mM Ca2+ PSIM formed 
larger, branched aggregates (arrows in Figure 2.6A). At 5 mM Ca2+, the aggregates were 
closest (Figure 2.6B). Most of spaces (> 95%) between the aggregates were less than 5 µm, 
which was significantly greater than the aggregate spacing for 1 mM (P < 0.05). At 1 mM 
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Ca2+, about half (49.8%) of the spaces were 5 - 10 μm, which was significantly greater than 
the percentage of spaces at 5 mM (~ 5%; P < 0.05). At 10 and 20 mM Ca2+, there were 
more large spaces (15 - 20 and 20 – 25 μm) between aggregates than at 1 and 5 mM (P < 
0.05). At these higher Ca2+ concentrations, PSIM aggregates formed islands with low inter-
particle distances (< 5 µm) and higher distances (> 5 µm) between islands (Figure 2.6A). 
These large spaces between islands created pores through the PSIM layers. At 1 mM Ca2+, 
about 3% of the surface area was covered by PSIM aggregates (Figure 2.6C). Increasing 
the Ca2+ concentration to 5 mM increased area covered 15-fold (P < 0.05). Further increase 
in the Ca2+ concentration to 10 mM reduced the area coverage to 18%. Similar to the 
aggregate distribution, no significant difference in the area coverage was observed if Ca2+ 
concentration was increased from 10 to 20 mM Ca2+.  
 
Molecular retention within PSIM layers was dependent on Ca2+ concentration (Figure 
2.6D-G). As with the transmitted light measurements (Figure 2.6A), the size of PSIM 
aggregates increased with increasing Ca2+ concentration (Figure 2.6D). Green fluorescence 
from FITC-dextran, which indicates the location of molecules retained in the PSIM layers, 
became patchy with increasing Ca2+ concentration (Figure 2.6D). With an increase in 
calcium concentration from 1 to 5 mM, the average GFP fluorescence decreased (P < 0.05; 
Figure 2.6E), indicating a decrease in the number of molecules retained in the PSIM layer. 
A further increase in calcium concentration to 10 mM, reversed this direction and increased 
the average GFP fluorescence (P < 0.05; Figure 2.6E). The local structure of the PSIM 
aggregates explains this behavior (Figure 2.6F). Regions of high PSIM aggregation (stars 
in Figure 2.6F) had low GFP intensities. Pores in the PSIM layer, identified as regions with 
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low red fluorescence (dashed circles in Figure 2.6F), had high GFP fluorescence. The GFP 
intensity in the pores was greater than in the aggregated material (P < 0.05; Figure 2.6G), 
indicating exclusion from PSIM aggregates.  
 
2.3 Discussion 
We have developed a new method for isolating mucus from the porcine intestine (Figure 
2.1). This method dissolves the mucus layer from intact intestines using NaOH. A dilute 
(0.01 M) solution was used because it dissolved most of the mucus layer (Figure 2.1E and 
1G) and caused minimal damage to the epithelial cell layer (Figure 2.1F). Minimizing the 
damage reduced the amount of contaminating proteins in the purified mucus (Figure 2.1G). 
A sol-to-gel transition in the extraction method (Figure 2.1H) eliminated pH-unresponsive 
macromolecules and cellular proteins without the use of high-cost instrumentation. 
Solubilized mucus proteins were recovered with a yield of 1274 mg per meter length of 
small intestine. The biophysical and biochemical properties of the produced mucus are in 
line with those reported previously58, 66, 70, 81. At acidic pH values, PSIM becomes more 
gel-like, with increasing viscous and elastic moduli (Figure 2.2D). With increasing 
concentrations of calcium, the extent of PSIM aggregation at neutral pH increases (Figure 
2.4B). The thickness of the PSIM layer formed in the in vitro mucus model has a thickness 
comparable to the mucus layer in the small intestine58 (Figure 2.5B).   
 
This new process has several advantages over other methods. Compared to direct scraping 
of mucus from the epithelial lining, solubilization of mucus greatly simplifies the extraction 
process. Dissolving mucus in dilute NaOH and purifying with a sol-gel transition 
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significantly decreases contamination with cellular debris (Figure 2.1G). In immunogenic 
experiments, contamination with cellular or bacterial component could cause unwanted 
responses. In addition, the process is scalable and can be applied to entire lengths of PSI 
tubes simultaneously. Compared to commercial mucin, PSIM retains the rheological 
properties of natural mucus. Commercial mucins do not form a gel (Figure 2.S5), which 
limits their use as a barrier in experiments in vitro33. Compared to mucin extraction 
protocols, this process does not require extensive downstream equipment87-88. Most of 
these methods are limited by the quantity and yield of mucus that can be produced, which 
prevents the widespread use of mucus in research.  
 
The extraction of large volumes of mucus enabled many of its properties to be quantified. 
An important property that was observed was the reversibility of pH and calcium-induced 
aggregation and gelation (Figure 2.2G and 2.4C). Reversibility suggests that the properties 
of mucus respond to conditions in the local environment. This dynamic change was easily 
monitored because the absorbance at 410 nm was directly correlated to the degree of 
aggregation (Figure 2.2C and 2.2F) and the viscous and elastic moduli (Figure 2.2D). 
Reconstituted PSIM retained the ability to be a barrier to bacterial penetration (Figure 2.3) 
and this property was dependent on pH. At neutral pH, mucus only minimally prevented 
penetration, but when the mucus aggregated at lower pH, penetration was considerably 
reduced (Figure 2.3A-D). The aggregation of the mucus at pH 4 appeared to slow 
penetration because the bacteria became immobilized in aggregated mucus. A gel layer of 





Another observation was that calcium plays a critical role in the intestinal milieu. Similar 
to pH, the availability of calcium ions affected the thickness of the mucus layer (Figure 
2.5B). Increasing the calcium concentration increased PSIM aggregation, suggesting that 
calcium affected PSIM by similar mechanisms as changes in pH. In addition, there was an 
interplay between the responses of mucus to pH and calcium. Overall, acidic pH had a 
greater effect on mucus aggregation than calcium concentration within the physiological 
range (Figure 2.4B). At neutral pH and in the absence of calcium, mucus was not 
aggregated. Increasing the calcium concentration increased mucus aggregation but did not 
reach the same extent as that observed at pH 4 (Figure 2.4B). Calcium-driven aggregation 
also affected the barrier function. From low (5 mM) to high (20 mM) physiological levels 
of calcium 76, 78, the molecular permeability of mucus increased (Fig 2.5C).  
 
The microscopic structure of mucus explains how calcium controls the barrier function of 
mucus. The primary microscopic features that affects the physical properties of mucus are 
the arrangement and density of aggregates. At very low calcium levels (1 mM), mucus 
aggregation is minimal (Figure 2.6A). At low physiological calcium concentrations (5 
mM), small and uniform aggregates begin to appear. At higher calcium concentrations (10 
- 20 mM), larger, more branched aggregates form. The branching of mucin aggregates did 
not increase once Ca2+ concentration was higher than 10 mM. Although the density of 
aggregates increases, this condensation decreases the surface area coverage (Figure 2.6C). 
The branched nature of the aggregates formed void spaces in the mucus layer (Figure 2.6D) 
that increase molecular diffusion while also increasing the thickness of the layer (Figure 
 
24 
2.5A). The structure and extent of these aggregates explains how calcium increased both 
mucus layer thickness and molecular transport.  
 
These effects suggest how the local calcium concentration controls the properties of the 
mucus barrier (Figure 2.7). The increased concentration of ionic molecules after ingesting 
food (predominantly calcium) induce mucin aggregation and increases the thickness of the 
mucus barrier. The increased aggregation increases molecular permeability (Figure 2.6), 
while simultaneously increasing resistance to microbial penetration from the lumen. If the 
behavior of PSIM in high calcium is similar to pH 4, where both had considerable 
aggregation (Figure 2.4B), then PSIM aggregation at high calcium would also have high 
resistance to microbial penetration from the lumen (Figure 2.3 and Figure 2.5). Therefore, 
dense branched aggregates increase the open channels for molecular diffusion while also 
creating a network to ensnare invasive microbes. As the mucus flows along the epithelium 
its viscoelastic and barrier properties change in response to the lumen content. Because the 
properties of the mucus are reversible, it is instantaneously responsive and serves different 






Figure 2.1 Extraction of porcine small intestine mucus (PSIM). (A) Schematic of mucin 
microstructure, stable polymeric chains at neutral pH, hydrophobic interactions of cysteine 
rich regions at acidic pH (dashed circles), and ionic interactions between calcium ions 
(Ca2+) and negatively charged glycans at neutral pH. (B) Mucus extraction procedure 
starting with direct solubilization of the mucus layer with NaOH, and separation of pH 
responsive mucus via reversible sol-gel transition. (C) PSI tubules after 24 hours exposure 
to 1 M HCl, PBS, and 1 M NaOH. (D) The luminal surface of PSI tissue sections after 24 
hours exposure to HCl, PBS, and NaOH. (E) Recovered protein with solutions of different 
pH, relative to PBS. (*, P < 0.05; n = 3). (F) Hematoxylin and Eosin (H&E) stained 
histological sections of PSI tissues treated with different pH solutions. Inner panels show 
individual villi. (G) H&E stained PSI section after 0.01 M NaOH treatment. (H) Total 
protein extracted when PSI tubules were filled with NaOH solutions ranging from 0.001 
M to 1 M (n = 3). (I) Total protein content with repeated sol-gel cycles relative to initial 
total protein extracted. (J) Total DNA content with repeated sol-gel cycles relative to the 





Figure 2.2 Response of PSIM to pH. (A) PSIM (20 mg/ml) in 20 mM HEPES at pH 7.3 
was clear. At a pH of 5.3 the PSIM solution was turbid. Returning the pH to 7.2, after 
decreasing it to 5.3, restored optical clarity. All solutions were at 20 mg/ml concentration 
unless otherwise noted. (B) PSIM (80 mg/ml) in 20 mM HEPES at pH 7 was a viscous 
solution (left tube, left image) that flowed after inversion (left tube, right image). At pH 4, 
PSIM was a gel (right tube, left image) that did not flow after inversion (right tube, right 
image). (C, top) Droplets of PSIM (20 mg/ml) on a glass slide imaged using a stereoscope. 
Darkness was due to the turbidity of the droplets. (C, bottom) Absorbance of PSIM 
solutions (20 mg/ml) at different pH values at a wavelength of 410 nm. (D) Dynamic 
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rheological moduli (G՛ and G՛՛) of PSIM at pH 2, 4, and 7 and at 1 Hz and 37oC (n = 3, 
mucus from individual pigs). (E) Microscopic images of PSIM between two glass 
coverslips in the pH range 2-7. Insets show close-up images of aggregates. (F) Surface area 
covered by PSIM aggregates per image (as in panel E) in the pH range 2-7 (n = 10). (G) 
Real-time sampling and characterization of the reversible aggregation of PSIM in the pH 
range 4-8. The solid line represents an increase in the absorbance as the pH was reduced 
from 8 to 4 (red arrows). The dotted line represents the decrease in absorbance (blue 






Figure 2.3. Barrier function of PSIM. (A) Time-resolved transmigration of E. coli 
through 3 µm pore transwell membranes layered with PSIM at pH 7, 4, and 2. Controls 
were HEPES buffer at pH 7 without PSIM (n = 3). (B) Transmigration of Salmonella. (C) 
Number of E. coli that migrated across the PSIM layers at 6 h time point. (D) Number of 
Salmonella that migrated across the PSIM layers at 6 h. (E) The speeds of individual 
bacteria were measured in hanging drops of PSIM mixed with bacteria and suspended 
above the objective of an inverted microscope. At pH 7 (top), velocities (indicated by line 
lengths) were greater than at pH 4 (bottom), where all bacteria were visibly non-motile. (F) 
The average speeds of E. coli and Salmonella in PSIM at pH 4 were significantly lower 
than PSIM-free controls at pH 4 (*, P < 0.05; n = 3). At pH 7, PSIM had no effect on 
bacterial motility compared to control. (G) Distribution of speeds of E. coli in PSIM at pH 
4 and 7 compared to controls (HEPES buffer without PSIM; n = 3). The percentage of 
bacteria with speeds less than 2 µm/s was greater in PSIM at pH 4 compared to pH 7 and 
controls (*, P < 0.05). The percentage of bacteria swimming at 5 µm/s was lower in PSIM 
at pH 4 compared to pH 7 and controls (*, P < 0.05). (H) The distribution of speeds of 





Figure 2.4. Calcium regulates the physical properties of PSIM. (A) Stereoscope images 
of PSIM at pH 4 and 7 with Ca2+ ranges from 0 to 10 mM. Scale bar is 1 mm. (B) The 
absorbance of PSIM at 410 nm and pH 7 increased with increasing Ca2+ concentrations of 
0, 1, 5 and 10 mM (*, P<0.05; n = 3). Absorbance did not change at pH 4. (C) The 
absorbance of PSIM at 410 nm and pH 7 with 100 μl Ca2+ (+Ca2+) was greater than control 
PSIM without Ca2+ (*, P < 0.05; n = 3). A second addition of 100 μl Ca2+ (++Ca2+) further 
increased absorbance.  The absorbance was reduced by adding 100 μl EDTA (+EDTA), a 
Ca2+ chelator, compared to +Ca2+ and ++Ca2+ (*, P < 0.05). Inset images are snapshots of 
PSIM solutions at the different Ca2+ conditions. Scale bar is 10 mm. (D) Microscopic 
images of reconstituted PSIM (2% w/v) between two glass coverslips in pH range 2-7 with 
1 mM Ca2+. Insets show close-up images of the aggregates. (E) The surface area covered 
by PSIM aggregates with 1 mM Ca2+ was greatest at pH 4 compared to pH 2- 3 and pH 5-
6 (*, P < 0.05; n = 10). At pH 7 (inset), The surface area covered by PSIM aggregates with 







Figure 2.5. Calcium controls the thickness of the mucus barrier. (A) Cross-section 
images of PSIM gel layers formed on transwell membranes at 1, 5, 10, and 20 mM Ca2+ 
and pH 7. (B) PSIM layer thickness increased linearly with Ca2+ concentration. The 
thicknesses at 10 and 20 mM were greater than at 5 and 10 mM, respectively (*, P < 0.05; 
n = 3). (C) Concentration of FITC-dextran after transport through a PSIM layer formed on 
a transwell membrane in the presence of 1, 5, 10, and 20 mM Ca2+ at pH 7. (D) 
Concentration of FITC-dextran at 6 hrs after transport through the PSIM layers in (C). The 
concentration was greatest with 1 mM Ca2+ compared to all other concentrations (*, P < 
0.05; n = 5). The concentration of FITC-dextran was less at 5 mM compared to 10 and 20 





Figure 2.6. Calcium controls the porosity of the mucus barrier. (A) Microscopic images 
of PSIM aggregates at 1, 5, 10, and 20 mM Ca2+ and pH 7. Higher resolution images show 
homogeneous, dense, and small PSIM aggregates at 5 mM Ca2+. (B) Distribution of 
distances between PSIM aggregates as a function of Ca2+ concentration. The percentage of 
distances less than 5 µm was greater at 5 mM compared to 1, 10 and 20 mM (*, P < 0.05; 
n = 5). The percentage of distances between 5 and 10 μm was greater at 1 mM compared 
to 5 mM (*, P < 0.05). The percentage of distances between 15 and 25 μm was greater at 
10 and 20 mM compared to 1 and 5 mM (*, P < 0.05). (C) The surface area covered by the 
PSIM-aggregates at 5 mM was greater than at both 1 and 10 mM Ca2+ (*, P < 0.05; n = 
10). (D) Fluorescent microscopic images of Cy5-lectin-tagged PSIM layers (red, left) and 
overlaid with FITC-dextran (green, right) at 1, 5, 10, and 20 mM Ca2+. (E) The average 
GFP fluorescence (in relative fluorescence units, RFU) was less at 5 mM compared to 1, 
10 and 20 mM (*, P < 0.05; n = 5). (F) Expanded images of pores (dashed lines) and 
aggregates (stars) formed in PSIM layers at 10 and 20 mM Ca2+. (G) The fluorescence 
intensity of FITC-dextran in pores was greater than in aggregates at both 10 and 20 mM 





Figure 2.7. Role of calcium as a regulator of molecular transport. Proposed dynamic 
regulation of the thickness and permeability of the small intestine mucus barrier in response 





2.4 Materials and Methods 
All chemicals and supplies were purchased from Fisher Scientific and Sigma Aldrich 
unless otherwise specified.   
 
2.4.1 Natural mucin extraction from a porcine small intestine 
Small intestines from freshly slaughtered pigs were obtained from a local slaughterhouse 
and transported to the laboratory on ice within 2 hours. Porcine small intestines (PSIs) were 
cut into 6-inch long segments and washed with running DI water. The tissues were filled 
with 50 ml of 1M HCl, 1x PBS, and 1M NaOH. After both ends are tied, PSI tubules were 
incubated at 4 ºC for 24 hours. The solutions were collected and aliquoted into 1 ml 
Eppendorf tubes and centrifuged in a microcentrifuge at 10,000 x g for 30 minutes. The 
supernatant was collected, and total protein was quantified using a Bradford assay. Bovine 
serum albumin was used as a standard for known protein concentration. For optimization 
of NaOH concentration, cleaned PSIs (6-inch, n=3) were filled with 10 ml of serially 
diluted NaOH solutions (1, 0.1, 0.01, and 0.001 M) and incubated at 4 ºC for 24 hours. The 
solutions were collected and stored at -80 ºC. To quantify total soluble protein, the frozen 
solutions from all four conditions were thawed at 4 ºC, vortexed thoroughly, and divided 
into 1 ml aliquots. The aliquots were centrifuged in a microcentrifuge at 10,000 x g for 30 
min. Supernatant from 3 aliquots were dialyzed against DI water in a cellulose membrane 
(molecular size cut-off = 14 kDa) for 72 hours at 4 ºC with a water change every 12 hours. 
The dialyzed solution was lyophilized to quantify the dry mucus weight and reconstituted 





For the scale-up, PSIs (2 meter) were flushed with running tap water to remove the luminal 
content and the loosely bound mucus layer. The luminal space was then filled with 350 ml 
0.01 M NaOH with both ends tied and incubated at 4 °C for 24 hours. The solubilized 
mucus extract was collected and centrifuged at 20,000 x g for 2 hours at 4 ºC to precipitate 
debris in 50 ml tubes. After collecting the clear supernatant, the pH was adjusted to 4 to 
induce PSIM aggregation. Aggregated PSIM was separated by centrifugation at 200 x g 
for 15 minutes and resuspended to get a clear solution in sterile DI water by adjusting pH 
to 8.0-8.5. The solubilized PSI was filtered through a 40 μm strainer and dialyzed 
(molecular size cut-off = 14 kDa). The dialyzed mucus extract was sterilized by adding 1% 
(v/v) chloroform under constant stirring at 4 ºC for 72 hours. The sterile solution at a pH 
of approximately 7, was frozen at -80 ºC, lyophilized, and stored as a powder at -20 ºC 
until used. All the experiments were conducted using the lyophilized powder reconstituted 
in an appropriate buffer or cell culture medium and the term PSIM is used to denote the 
reconstituted form at a known concentration. The theoretical density of mucin protein in 
the intestine was calculated by considering the surface area increased due to the intestinal 
folds and the villous architecture. 
 
2.4.2 Histological sectioning of the intestinal tissues 
Tissues were cut into 2 cm sections and excess water was removed. Tissues were embedded 
in optimum cutting temperature (OCT) cryomatrix and snap frozen in liquid nitrogen. 
Using a cryostat (Thermo Scientific, CRYOSTAR NX70), frozen tissues were sectioned 
at a 20 µm thickness. Sections were fixed with 10 % formalin and stained with hematoxylin 
and eosin (H&E).  
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2.4.3 Biophysical characterizations of the reconstituted mucus 
1. Rheological characterization. Bulk rheology on reconstituted PSIM samples from 3 
different pig intestines was conducted. Small amplitude oscillatory shear measurements 
were performed in a Kinexus Pro rheometer (Malvern Instruments, U.K.) using a cuvette 
cell geometry. PSIM samples were loaded into the cup at pH values of 2, 4, and 7 and held 
at a constant temperature of 37 °C. Oscillatory frequency sweeps were conducted between 
1 and 100 Hz at a constant 0.25 % strain.  
 
2. Absorbance characterization. PSIM aggregation was quantified using UV-vis 
spectroscopy. The absorbance value at 410 nm was used as a measure of PSIM aggregation. 
Lyophilized PSIM powder was reconstituted in 20 mM HEPES at pH 7. The pH value of 
the reconstituted PSIM was adjusted using 2 M HCl and 2 M NaOH. 100 μl of PSIM 
samples were added to a 96-well plate and the absorbance was measured using a microplate 
reader (Synergy H1, BioTek).  
 
3. Microscopic characterization of PSIM aggregates. Twenty microliter droplets of 
PSIM solution were placed between glass coverslips and clear glass slides and were imaged 
using a brightfield microscope (EVOS). The images were binarized using a built-in scheme 
in the image analysis software ImageJ. The area covered by aggregates per image was 
quantified and plotted as percentage area covered normalized by the total area of the image.  
 
4. Dynamic viscoelastic characterization. PSIM 2 % (w/v) at pH 7.3 was added to a glass 
vial and subjected to constant stirring. The pH was monitored in real time using a needle-
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type pH probe (PreSens) and was adjusted using 2N HCl and 2N NaOH solutions. Samples 
were collected at specific pH values for UV absorbance measurements. 
 
2.4.4 Bacterial cell culture 
Two bacterial strains S. typhimurium (SL1344) and E. coli (MG1655) were used for live 
bacterial experiments. Frozen stocks of the bacterial strains were inoculated in Luria Broth 
(LB) and grown overnight. Optical density at 600 nm (OD600) of the overnight cultures 
was measured and the bacteria were seeded at a density of 1x107 in fresh LB medium and 
allowed to grow to an OD600 of 0.6-0.8 and used for further experiments. 
 
2.4.5 Two-dimensional bacterial motility assay in PSIM on a glass slide 
Live bacterial imaging was performed in a hanging drop assembly for bacterial motility 
quantification. Bacteria cultured in LB were diluted 1:10 in PSIM (2 % w/v) or control (20 
mM HEPES solution), and a 2 μl droplet was added on top of a circular cover glass. The 
cover glass with the droplet was inverted and rested on top of a 1mm thick PDMS ring 
bound to a glass slide. The glass slide with the hanging drop was imaged using an inverted 
fluorescent microscope (Zeiss). Bacterial movement was tracked in a single 2D plane and 
the average speed was quantified using the in-built particle tracker plug-in ‘Trackmate’ in 
ImageJ software. 
 
2.4.6 Three-dimensional bacterial diffusion assay through PSIM in transwell inserts  
HEPES solution (20 mM) was added to transwell inserts (50 μl/transwell) and used as the 
no barrier condition and compared to 50 μl of PSIM 2 % (w/v) at pH values of 2, 4, and 7. 
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Transwell inserts were placed into the wells of a 24-well plate containing 600 μl of LB. A 
100 μl of live bacterial culture (1011 cells/ml) was gently added to the inserts and the plates 
were incubated at 37 ºC and 5 % CO2. Fluorescence intensity was measured at 1-hour 
intervals for 6 hours in the bottom well and converted to colony forming units (CFUs) 
using a previously established standard curve. 
 
2.4.7 Fixation and cryo-sectioning of PSIM layers on transwell membranes  
Transwell inserts with different PSIM gel layers formed in response to added Ca2+ were 
held vertical. A small cut was created on the edge of the membrane from the bottom side. 
The inserts were kept on tissue paper to absorb all liquid from the membrane and mucin 
gel. Transwell inserts were transferred into wells of 24 well plate containing 600 μl of 10% 
formalin solution in PBS. Formalin (10% in phosphate buffered saline) solution was gently 
added on the apical side of the transwell and kept at room temperature for 10 minutes. 
Inserts were moved to a different well and the formalin solution was carefully replaced by 
PBS 3 times on apical and basal sides. The membranes were dehydrated again using tissue 
paper and carefully cut out from the inserts using a scalpel. The membranes were embedded 
in OCT and snap frozen in liquid nitrogen. Frozen membranes were cross sectioned at a 10 
µm thickness using a cryostat and collected on glass slides. The sections were imaged using 





2.4.8 Lectin staining for visualization of PSIM aggregates 
Far-red-fluorescence (Cy5)-conjugated Sambucus Nigra (SNA) lectins (Vector Labs) were 
added to PSIM 2 % (w/v) at a final concentration of 10 µg/ml and incubated at room 
temperature for 30 minutes. The solution was dialyzed against DI water for 24 hours 
constant stirring in a dark room at 4 ºC. The fluorescent lectin tagged PSIM was used to 
visualize PSIM aggregates using fluorescence microscopy. 
 
2.4.9 Pore size distribution  
Aggregates were imaged microscopically in PSIM (2 % w/v) containing 1, 5, 10, and 20 
mM Ca2+. Inter-aggregate distance was measured at 100 random locations per image using 
ImageJ. An average number distribution (%) of at least 5 independent images from each 
condition was plotted in a range of 0 - 30 μm.  FITC-dextran diffusion was measured at 
different calcium concentrations. HEPES solution (20 mM) was added to the wells of a 24 
well plate (600 μl/well). PSIM solution 2 % (w/v) in 20 mM HEPES at a pH of 7 and 
containing 1, 5, 10, and 20 mM Ca2+ was added to transwell inserts (100 μl/transwell). 
Transwell inserts were placed into the wells of 24 well plates containing 600 μl of HEPES 
solution and the well plate was incubated for 12 hours at 37 ºC and 5 % CO2 to allow for 
mucus layer formation. A 10 μl droplet of 10 mg/ml solution of FITC dextran (MW= 20 
kDa) in DI water was gently added to the inserts and the plate was incubated at 37 ºC and 
5 % CO2. Fluorescence intensity was measured at 1-hour intervals for 6 hours in the bottom 




2.4.10 Fluorescent imaging and area overlap analysis 
PSIM 2% (w/v) at pH 7 and containing 1, 5, 10, and 20 mM Ca2+ was added to a 96-well 
plate (100 μl/well). The well plate was incubated overnight at 37 ºC and 5 % CO2 to allow 
for mucus layer formation. FITC-dextran (MW = 20 kDa) at a concentration of 10 mg/ml 
in 20 mM HEPES was gently added to the transwells (10 μl/transwell) and the plate was 
incubated at 37 ºC and 5% CO2. Fluorescent images using were captured using a Zeiss 
Axiovert 4-laser spinning disc confocal microscope (20x magnification) after 1 hour. 
Image analysis for GFP intensity (FITC-dextran) and RFP intensity (Cy5 lectin tagged 
PSIM) was performed using ImageJ and normalized for the total area of the images. Areas 
with bright RFP intensity were considered as ‘aggregate’ and low RFP intensity areas as 
‘pore’. The average intensity of FITC was determined in the entire image and in the pore 
and aggregate regions. 
 
2.4.11 Statistical analysis 
A two-tailed Student’s t-test assuming unequal variances was used for statistical analysis 
of different conditions. One-way ANOVA with Bonferroni post-hoc test was used for 
multiple comparisons. Differences were considered significant at p < 0.05. All data are 






MODEL OF INTESTINAL MUCOSA TO QUANTIFY THE ROLE OF MUCUS 
AND EPITHELIAL BARRIER IN REGULATING THE HOST INNATE 
IMMUNE RESPONSES TO PROBIOTIC AND PATHOGENIC BACTERIA  
 
3.1 Introduction 
In the intestines, three major components mediate the host-response to pathogens and the 
gut  microbiota: the mucosal barrier, the epithelial layer and tissue-resident immune cells 
97. The interactions of these components in pathophysiological conditions are poorly 
understood. Two major disease states result from disruption of these protective 
mechanisms, acute enteropathogenic infections, and chronic inflammatory bowel diseases 
(IBD) 98-99. The mucus layer is the first line of defense, which plays a critical role in the 
prevention of enteropathogenic infections. In the healthy colon, the secreted mucus layer 
that covers the entire epithelium minimizes interactions of commensal bacteria with host 
cells 63, 100. Dysfunction of the mucus layer and bacterial infiltration are linked to tissue 
inflammation and disease 47, 49, 101-102. During enteropathogenic infections, bacteria can 
penetrate intestinal regions of disrupted mucus 103-105, but there is recent evidence that 
bacteria can also penetrate regions with intact mucus 106. A better understanding of the 
interaction between microbes and the protective host mechanisms could lead to improved 
treatment for intestinal diseases.  
 
The responses of epithelial and immune cells to bacterial infiltration are difficult to 
decouple from in vivo measurements and are poorly understood. The epithelial barrier and 
cells of the innate immune system collectively function as the subsequent layers of 
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protection after the mucus layer 107. In the colon, tight junctions between epithelial cells 
prevents transmigration of pathogens into underlying tissue 108. Colonic epithelial cells 
produce chemokines, such as interleukin-8 (IL-8), that attract neutrophils and other effector 
cells of the innate and adaptive immune system 109. Monocytes, which are innate immune 
cells, detect pathogens directly as well as respond to epithelial derived signals. One 
response to these stimulants is differentiation into macrophages and dendritic cells 110-111. 
LPS and flagellin are common pathogen associated molecular patterns (PAMPs) that bind 
to toll-like receptors (TLR4 and TLR5) and activate the downstream pathways that cause 
pro-inflammatory cytokine secretion 112-114. Immune-cell-derived tumor necrosis factor 
(TNF-α) is a cause of systemic inflammation. Both TNF-α and IL-8 levels are significantly 
upregulated in the intestines of patients with IBD 115-116.  
 
A common enteropathogenic infection is Salmonellosis 117-118. Salmonella enterica subsp. 
enterica serovar Typhimurium is a foodborne pathogen that causes diarrhea and can often 
be fatal 118. In humans, infection with Salmonella or other enteropathogenic bacteria is 
linked to higher incidence of IBD 119-121. Studies have shown that attachment of Salmonella 
to mucus is a critical step for infection 122-125. In mouse models, Furter et al. showed that 
Salmonella infects the colonic epithelium even when covered with a thick layer of mucus 
106. This recent observation contradicts the common notion that the mucus barrier serves as 
a sticky net to trap the invading luminal microbes 126. How Salmonella penetrate the mucus 




Murine models are the most common method to study the gastrointestinal biology. 
However, studying the complex interactions between luminal microbes, tissue immune 
cells and the mucosal barrier in living animals is challenging. Alternately, in vitro platforms 
are well suited to studying these complex interactions. For example, three-dimensional 
biomaterial platforms have been developed to mimic the morphology of the epithelial layer 
12, 127. Epithelial and immune cell interactions are commonly measured in transwell-based 
platforms 128-129. Flow based microfluidic platforms have enabled long-term co-culture of 
gut-representative microbial communities 16-17, 130. Incorporation of mechanical forces 
within microfluidic platforms induced three-dimensional villus differentiation and allowed 
quantification of communication between bacteria-epithelial-immune cell compartments 
11, 15, 130.  
 
The inclusion of a mucus layer is critical because of its role in mediating bacteria-epithelial 
cell interactions. Some cultured epithelial cells secrete mucus and form mucus layers that 
enable the quantification of drug and molecular interactions with mucus 131-132. Two recent 
studies demonstrated thick mucus layer secretion from primary human colonic epithelial 
cells using air-liquid interface in transwell culture or colon-on-a-chip microfluidic culture 
133-134. Most cultured cell lines, however, do not generate a layer matching physiological 
thickness of colonic mucus. Due to insufficient mucus secretion from cultured human 
epithelial cells, porcine gastric mucin (PGM) has been used as human mucin substitute 34-
35. PGM has been used to recreate the intestinal mucus layer by mixing with agar and 
forming a solid interface with luminal solution that supported bacterial attachment and 
growth 16-17. However, stomach mucus has different physicochemical properties than 
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intestinal mucus and commercially available PGM does not undergo sol-gel transitions 135. 
An alternative to PGM is purified intestinal mucus. It has been shown that MUC2, which 
is purified from intestinal mucus, has antiviral activity and attenuates the virulence of 
pathogenic bacteria 136-137. We have developed a method to extract porcine small intestinal 
mucus (PSIM). Reconstituted PSIM undergoes sol-gel transitions with changes in pH and 
ion concentrations, similar to native intestinal mucus 138. Low pH caused mucus 
aggregation and reduced bacterial transport, and moderate calcium concentrations formed 
microscopic aggregates that impeded molecular diffusion.  
 
Here, we demonstrate a model of intestinal mucosa to quantify the role of mucus and 
epithelial barrier in regulating the host innate immune responses to probiotic and 
pathogenic bacteria. We hypothesize that mucus prevents the penetration of bacteria 
through the intestinal lining and that the motility of pathogenic bacteria affects their 
penetration and immune response. To decouple the host-microbe interactions, mucus and 
epithelial layers were developed in a physiological form on transwell membranes. The 
porous transwell membrane enabled molecular communication between human epithelial 
(HT-29) cells and human monocytic (THP-1) cells. The hypotheses were tested with 
commensal VSL#3 bacteria, wild-type SL1344 Salmonella, and a non-motile flhDC 
knockout strain of Salmonella. Bacterial penetration, immune cell differentiation, and 
cytokine release were quantified using fluorescent immunostaining, microscopic imaging, 
and ELISA. The effects of a mucus layer on bacterial transmigration and molecular 
diffusion were quantified using fluorescent spectroscopy. This intestinal mucosa model 
enabled the quantification of the differences in the integrity of mucosal barrier compared 
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to epithelial barrier alone when challenged with live bacteria. This mucosal barrier model 
enabled the measurement of bacterial penetration, immune cell differentiation and cytokine 
release. Understanding the mechanisms of action of probiotics or pathogens when in 
contact with the mucosal barrier will lead to development of therapies for bacterial 
infections and immunological diseases of the intestine. 
 
3.2 Results 
3.2.1 PSIM formed a gel layer on top of epithelial cells without affecting cell 
viability.  
We have developed a method to mechanistically study the host-microbe interactions at the 
mucosal interface of the intestines. A mucus gel layer was reconstituted on top of epithelial 
cells growing on transwell membranes (Figure 3.1). Human colonic epithelial cells (HT-
29) genetically labeled to express red fluorescent protein (RFP) covered the entire surface 
of the transwell membrane and coverage was not affected by the presence of PSIM (Figure 
3.1A). PSIM (20 mg/ml) was added to the epithelial cells and after 12 hours it formed an 
opaque gel layer in situ that was structurally porous (Figure 3.1B). This 12-hour incubation 
at 37 °C reduced the thickness of the PSIM layer (Figure 3.1C). Initially, the total height 
of solubilized PSIM (100 µl/well) layered on top of epithelial cells was approximately 2.7 
mm. Final thickness of the gel layer formed was 880 ± 230 µm (Figure 3.1B). The PSIM 
gel layer formation was robust and the structure was maintained after cryo-freezing and 
histological sectioning. PSIM formed a tightly bound gel layer and did not affect the 
viability of HT-29 cells (Figure 3.1D). No significant difference was observed in the live 
(green) and dead (red) cell area coverage between the presence and absence of a PSIM 
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layer (Figure 1E). DAPI (4′,6-diamidino-2-phenylindole) staining of PSIM (red) showed 
that the PSIM gel layer has a fibrous structure (Figure 1F). When added, fluorescent wild 
type Salmonella (green) were suspended in the three-dimensional mucus matrix (Figure 
3.1F).  
 
3.2.2 PSIM is not immunogenic to epithelial or immune cells.  
To test its immunogenicity with human-derived cell lines, reconstituted PSIM was directly 
added to the monocultured HT-29 and THP-1 cells. PSIM mostly did not induce a pro-
inflammatory cytokine and chemokine response from HT-29 and THP-1 cells. HT-29 cells 
were cultured on the apical side of 24-well transwell inserts (Figure 3.2A) and IL-8 and 
TNF-α were quantified in the basolateral medium. HT-29 cells secreted a small but 
significantly higher amount of IL-8 in response to PSIM when compared to HT-29 cells 
alone (P < 0.05, Figure 3.2B). There was no difference in the amount of TNF-α secreted 
from HT-29 with and without PSIM application (Figure 3.2C). THP-1 cells were cultured 
in suspension in 24 well plates and IL-8 and TNF-α quantified in the culture medium 
(Figure 3.2D). PSIM did not induce IL-8 or TNF-α secretion from THP-1 cells compared 
to cells without PSIM (Figure 3.2E, F).  
 
3.2.3 Immunological responses from epithelial and immune cells are stimulant 
dependent.  
When cultured independently, HT-29 and THP-1 cells respond differentially after direct 
contact with bacterial antigen LPS, a set of 8 live probiotic bacteria (VSL#3), and 
pathogenic bacteria Salmonella. Intestinal epithelial cells have regular incidence of 
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bacterial contact, but immune cells only come in direct contact with live bacteria during 
bacterial infection events. The amounts of pro-inflammatory chemokine (IL-8) and 
cytokine (TNF-α) secreted from epithelial and immune cells were stimulant dependent. 
Salmonella induced a robust chemokine response in HT-29 cells, causing approximately 
24-fold higher IL-8 secretion compared to unstimulated cells (P < 0.01, Figure 3.3A). 
Direct contact of HT-29 cells with LPS or VSL#3 did not increase IL-8 secretion (Figure 
3.3A). LPS-stimulated THP-1 cells secreted 61-fold more IL-8 compared to unstimulated 
cells (P < 0.01, Figure 3.3B). Direct contact with VSL#3 and Salmonella each caused an 
approximately 30-fold increase in IL-8 secretion from THP-1 cells compared to bacteria-
free controls (P < 0.01, Figure 3.3B).   
There was no increase in the level of TNF-α secreted by HT-29 cells after direct contact 
with LPS or live bacteria compared to unstimulated cells (Figure 3.3C). TNF-α secretion 
from THP-1 cells was significantly increased when cultured with LPS or live bacteria 
(Figure 3.3D). LPS induced the highest TNF-α secretion and the level of TNF-α was 342-
fold higher compared to unstimulated THP-1 cells (P < 0.01, Figure 3.3D). Direct contact 
of THP-1 cells with VSL#3 (P < 0.01) and Salmonella (P < 0.05) caused 77 and 20-fold 
increases in TNF-α, respectively (Figure 3.3D).  
The morphology of THP-1 cells changed significantly when cultured in direct with VSL#3 
(Figure 3.3E). Change in morphology indicates the differentiation into macrophage and 
dendritic-like cells. THP-1 cells stimulated with VSL#3 induced approximately 6-fold 
increase in the number of differentiated cells per millimeter squared area (P < 0.01, Figure 
3.3F). Stimulation with LPS or Salmonella did not induce a change in morphology and 
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cells were mostly round (Figure 3.3E). Collectively, the results show that epithelial and 
immune cell activation and immunological responses are stimulant dependent. 
 
3.2.4 A PSIM gel layer prevents LPS induced immunogenic responses.  
In the co-culture platform, we hypothesized that the mucus layer would act as a physical 
barrier for molecular diffusion. Mucus layers prevented pro-inflammatory chemokine and 
cytokine secretion by human epithelial and immune cell co-culture in response to bacterial 
products. To test this hypothesis, epithelial-immune cell co-culture was used with and 
without mucus (Figure 3.4A). Co-culture of the HT-29 and THP-1 cells did not affect the 
basolateral levels of IL-8 and TNF-α when compared to monocultures (compare without 
mucus and without LPS in Figure 3.4B, C to Figure 3.2B, C, E, F). The addition of PSIM 
on the apical side of the epithelial layer caused no change in the levels of IL-8 and TNF-α 
(Figure 3.4B, C). LPS increased the concentrations of both IL-8 (P < 0.05, Figure 3.4B) 
and TNF-α (P < 0.05, Figure 3.4C) 4-fold in the absence of a PSIM layer. The presence of 
a mucus layer significantly reduced the levels of IL-8 (P < 0.05, Figure 3.4B) and TNF α 
(P < 0.05, Figure 3.4C) after LPS stimulation. The total amounts of IL-8 and TNF-α from 
the co-cultures were significantly lower compared to direct stimulation of THP-1 cells by 
LPS (P < 0.05, compare Figure 3.4B, C to Figure 3.3B, D). Collectively, the results show 
that the epithelial barrier attenuates immune cell stimulation by preventing direct contact 




3.2.5 A PSIM gel layer is a barrier to migration of live probiotic bacteria.  
To investigate the barrier function of the mucus layer in presence of commensal bacteria, 
we added a commercial probiotic mix VSL#3 to the HT-29 and THP-1 co-culture and 
measured the bacterial transmigration across the epithelial layer and the corresponding 
cytokine and chemokine responses. Without mucus, bacteria transmigrate across the 
epithelial layer to the bottom well (Figure 3.5A). The mucus layer reduced bacterial 
transmigration by 7-fold (P < 0.05, Figure 3.5B). Bacterial transmigration in the absence 
of a mucus layer induced THP-1 cell differentiation characterized by changes in 
morphology from round to elongated (Figure 3.5A). A 11-fold higher number of 
differentiated cells per millimeter squared surface area were present without the mucus 
layer when compared to the conditions containing a mucus layer (P < 0.01, Figure 3.5C). 
Due to increased bacterial loads, significantly higher concentrations of both IL-8 and TNF-
α were measured in the bottom well (P < 0.01, Figure 3.5D and P < 0.05, Figure 3.5E). The 
mucus layer reduced the IL-8 concentration by 16-fold (Figure 3.5D) and TNF-α 
concentration by 7-fold (Figure 3.5E). Immunohistostaining showed the spatial 
arrangement of the epithelial cell layer expressing epithelial cell adhesion molecule 
(EpCAM) at the base and the mucus layered on top of the epithelial surface. VSL#3 
bacteria that stained positive for nuclear stain DAPI were mostly seen on the outer surface 
of the mucus layer and few or no bacteria were present deeper in the mucus layer (Figure 
3.5F). Collectively, the results show that a reconstituted mucus layer reduced bacterial 
transmigration, thereby preventing direct contact between commensal bacteria and 
epithelial cells. The barrier effect leads to reduced epithelial damage by bacteria and 
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reduced proinflammatory cytokine and chemokine responses from the underlying immune 
cells. 
 
3.2.6 A PSIM gel layer enhances the transmigration of Salmonella. 
To test if active motility enables bacteria to transmigrate across the mucus layer, we used 
motile Salmonella. Surprisingly, the presence of mucus significantly increased the 
transmigration of wild type Salmonella and 3-fold more Salmonella transmigrated across 
the epithelial cell layers in presence of mucus (P < 0.05, Figure 3.6A). In the HT-29 and 
THP-1 co-culture, wild type Salmonella significantly increased the amounts of IL-8 and 
TNF-α in the presence of mucus and an epithelial layer compared to an epithelial layer 
alone (P < 0.05, Figure 3.6B, C). To test if these effects are controlled by flagella, a flagellar 
knockout (ΔflhDC) strain of Salmonella was created. The knockout caused a loss in 
Salmonella motility and the mean velocity was similar to VSL#3. Mean velocity of wild 
type Salmonella was significantly higher compared to the knockout strain and VSL#3 (P < 
0.05, Figure 3.6D). The presence of a mucus layer reduced the transmigration of knockout 
Salmonella across the epithelial cell layer (P < 0.05, Figure 3.6A). The amount of IL-8 was 
significantly lower in presence of a mucus layer compared to epithelial cells alone for 
knockout Salmonella (Figure 3.6B). The concentration of TNF-α in the medium with 
knockout Salmonella with or without a mucus layer (Figure 3.6C) was equivalent to basal 
levels from an unstimulated co-culture of cells (Figure 3.4C). Immunostaining showed the 
flagella of wild type Salmonella and the lack of flagella of knockout Salmonella (Figure 
3.6E). Histological sections of the mucosal layers on transwell membranes showed wild 
type Salmonella embedded deeper into the mucus layer (Figure 3.6F) than VSL#3 (Figure 
 
50 
3.5F). Within the gel layer, a significantly higher number of bacteria were found at the top 
and center of the mucus layer compared to the area proximal to the epithelial surface 
(Figure 3.6G). Collectively, these results show that motile Salmonella, in presence of 
mucus, utilize flagellar motility for higher transmigration across the mucus and epithelial 
layers. Higher transmigration caused significantly higher immune responses from the 
epithelial-immune cell co-culture. 
 
3.3 Discussion 
To gain a deeper understanding of how commensal and pathogenic bacteria interact with 
the mucosal lining of the intestine, we created an in vitro model of this barrier which 
consisted of a mucus layer, an epithelial cell layer and cells of immune system. These 
components represent essential complexities of the mucosal barrier. With this model we 
showed that the mucosal layer decreased the penetration of LPS and non-motile bacteria 
(Figure. 3.4&3.5). All bacteria tested in this study induced the production of cytokines and 
chemokines by THP-1 monocytes (Figure 3.3B, D). Additionally, Salmonella induced the 
production of IL-8 by HT-29 epithelial cells. In contrast, VSL#3 did not induce epithelial 
IL-8 production (Figure 3.3A, C). These results indicate that epithelial cells tolerate contact 
with commensal bacteria but respond to pathogens, whereas innate immune cells respond 
to all bacterial contact.  
 
This intestinal mucosa model was built upon the commonly used transwell platform, which 
enabled creation of epithelial and mucus gel layers, and co-culture with bacteria and 
immune cells (Figure 3.1). The mucus was not cytotoxic (Figure 3.1) and was 
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biocompatible to human epithelial and immune cells (Figure 3.2). The thickness of the 
mucus gel layer can be adjusted to match the thickness of mucus in different compartments 
of the gastro-intestinal tract (Figure 3.S1). The mucus layer caused spatial segregation of 
live commensal bacteria away from the epithelial layer and enabled co-culture studies up 
to 24 hours. The mucosa model demonstrated key mucus-layer-associated processes that 
have been reported in animal models but are difficult to reproduce in vitro. 
 
In this model, both mucus and epithelial cells formed a physical barrier to molecular 
diffusion and bacterial penetration. The amounts of IL-8 and TNF-α produced in the co-
culture system without mucus (Figure 3.4B, C) were lower than THP-1 cells directly 
stimulated with same amount of LPS (Figure 3.3B, D). When mucus was present, these 
amounts were further reduced (Figure 3.4). In the absence of the mucus layer, more bacteria 
crossed the epithelial cell layer (Figure 3.5D) and more monocytes differentiated (Figure 
3.5E). This dependence indicates that the mucus layer helps maintain the integrity of 
epithelial barrier in presence of commensal bacteria. The lack of production of TNF-α by 
epithelial cells indicates that inflammation is only induced after a breach in epithelial 
barrier and direct contact of live bacteria with immune cells. 
 
As a barrier, the mucus layer was more effective at preventing penetration of commensal 
bacteria (Figure 3.5) than immunogenic molecules (Figure 3.4). The transmigration of non-
motile commensal bacteria (VSL#3) across the epithelial layer was significantly lower in 
presence of mucus (Figure 3.5). With mucus, the amounts of IL-8 and TNF-α induced by 
VSL#3 were very low (Figure 3.5), similar to the amounts produced by unstimulated 
 
52 
epithelial and immune cells (-LPS in Figure 3.4). The difference in penetration between 
bacteria and molecules was most likely because of the structure of intestinal mucus. The 
mucus gel layer was porous as shown by histological sectioning and fluorescent confocal 
microscopy (Figure 3.1B, F). After gelation, intestinal mucus forms islands of aggregated 
protein that permit easier transmigration of small molecules than microbes and particulates 
138.  
 
An unexpected result was that the presence of mucus increased the penetration of 
Salmonella through the intestinal barrier (Figure 3.6). In comparison, mucus reduced the 
penetration of LPS (Figure 3. 3), and non-motile commensal bacteria (Figure 3.5). 
Salmonella transmigration followed complete penetration of the mucus layer and the 
epithelial barrier (Figure 3.6A). This effect was surprising because the penetration of 
Salmonella through mucus and an epithelial layer was greater than through an epithelial 
layer alone (Figure 3.6A-E), which was considerably thinner (Figure 3.1B). Flagella were 
required for this increase in transmigration through mucus (Figure 3.6A-E), showing that 
this phenomenon is dependent on bacterial motility. Two explanations for this observation 
are that mucus increases the motility of Salmonella by (a) attracting flagellated Salmonella 
or (b) inducing the production of flagella.  
 
The intestinal barrier responded in distinct ways to immunogenic molecules. The primary 
immunogenic molecules in Salmonella are LPS and flagellin, which are detected by toll-
like receptors (TLR) 4 and 5, respectively 113, 139. When LPS was applied to THP-1 
monocytes, they did not differentiate (Figure 3.3F). The LPS successfully crossed both the 
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mucus and epithelial barriers as indicated by the secretion of IL-8 and TNF-α (Figure 3.4). 
This result show that monocyte differentiation after contact with bacteria (Figure 3.3E) is 
controlled by a mechanism that is independent of LPS and TLR4. When knockout 
(ΔflhDC) Salmonella were applied to the intestinal barrier model, the THP-1 monocytes 
did not produce TNF-α (Figure 3.6C). This result suggests that the production of TNF-α is 
mediated by TLR5, the primary toll-like receptor to detect the flagella of Salmonella. 
 
Combined, these results paint a picture of how the intestinal barrier could react to contact 
with bacteria (Figure 3.7). In the healthy condition of an intact mucus layer and a lumen 
filled primarily with commensal bacteria (condition 1, Figure 3.7A), no bacteria penetrate 
the barrier layer and no cytokines are produced. When there is physical damage to the 
mucus layer (condition 2, Figure 3. 7B), commensal bacteria penetrate the epithelial layer 
and trigger the production of cytokines and chemokines by monocytes (Figure 3.5F, G). 
After this contact, the monocytes differentiate into macrophages and dendritic cells (Figure 
3.5C, E). Chemokines, e.g. IL-8, recruit neutrophils to contain the infection. When motile 
Salmonella are present in the lumen in significant amounts (condition 3), the mucus layer 
does not prevent penetration (Figure 3.7C). In this condition, the epithelial layer produces 
chemokines (Figure 3.3A) to recruit neutrophils before the pathogens cross the epithelial 
barrier. Once this barrier is breached, monocytes are activated, producing a similar immune 
response to an infection of commensal bacteria (Figure 3.3B, D and 6C, D). 
 
The intestinal mucosa model presented here provided insights into the role of mucus and 
epithelial barrier against bacteria and bacteria-derived molecular factors in presence of 
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innate immune cells. We envision that this platform will be useful for screening host 
response against pathogenic, opportunistic, and probiotic strains of bacteria. Many of the 
obtained results could only have been obtained with an in vitro system that includes the 
three essential components of the mucosal barrier: mucus, epithelial cells and immune 
cells. For example, it was found that the epithelial barrier is a key component of the innate 
immune response to bacterial infection, especially in the detection of pathogens. A better 
understanding of the relation between microbial pathogens, the intestinal barrier and the 
immune system has the potential to improve treatment of infections and immunological 
diseases. 
 
3.4 Materials and Methods 
All chemicals and supplies were purchased from Fisher Scientific and Sigma Aldrich 
unless otherwise specified. 
 
3.4.1 Human cell culture 
HT-29 (ATCC, HTB-38) adherent cells were cultured in McCoy’s 5A medium (Sigma 
Aldrich) supplemented with 2.2 g/L sodium bicarbonate. THP-1 (ATCC, TIB-202) 
suspension cells were cultured in RPMI-1640 medium (containing 0.05 mM β-
Mercaptoethanol). HEK293T/17 (ATCC, CRL-11268) cells were cultured in Dulbecco’s 
Modified Eagle Medium (DMEM). All media were supplemented with 10% fetal bovine 
serum (FBS) and 1% penicillin/streptomycin and referred to as complete medium in the 




RFP-expressing HT-29 cells were made by lentivirus transfection. For lentivirus 
production, HEK293T/17 cells grown in a 10 cm dish were transfected with four plasmids 
acquired from addgene: (4 μg pLV-mcherry (Cat #36084), 2 μg pMDLg/pRRE (Cat 
#12251), 2 μg pRSV-Rev (Cat #12253) and 2 μg pMD2.G (Cat #12259), using the standard 
calcium-phosphate co-precipitation method. Virus was harvested 24 h post transfection and 
filtered through 0.45 μm filter. For transduction, HT-29 cells cultured in six well plates 
were cultured in equal volumes of the virus containing medium and complete McCoy’s 5A 
medium. Cells were monitored for RFP expression and sub-cultured after most cells 
expressed RFP when checked for fluorescence qualitatively.  
 
3.4.2 PSIM extraction and purification 
PSIM was extracted as described before 138 with changes in sterilization procedure. Briefly, 
intact small intestine tubules were cut into 2-meter lengths and rinsed with water to 
eliminate food particles from the lumen. The tubules were drained gently, and the lumen 
was filled with 350 ml of 0.01 M NaOH. The ends of the tubules were tied and incubated 
for 24 hours at 4 oC. After incubation the solubilized material was drained by squeezing 
and collected. The extract was subjected to centrifugation at 20,000 x g (Thermo Scientific) 
at 4 oC for 2 hours to remove insoluble debris. The supernatant was collected without 
disturbing the precipitate. The clear supernatant was subjected to sol-gel transition by 
adjusting the pH to 4 using 2 M HCl. The aggregates formed at pH 4 were subjected to 
centrifugation at 200 x g for 15 minutes and resolubilized in sterile DI water by adjusting 
the pH value to 8. The solution was passed through a 40 μm strainer and subjected to 
dialysis using a membrane with molecular size cut-off equal to 14 kDa.  The dialyzed 
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mucus extract was sterilized by adding 1% (v/v) chloroform under constant stirring at 4 ºC 
for 72 hours. The solution (30 ml aliquots) was transferred to 50 ml conical polypropylene 
tubes, frozen to -80 oC, and freeze dried (Labconco Freezone 2.5L freeze dry system). The 
freeze-dried mucus was reconstituted aseptically in serum- and antibiotic-free McCoy’s 
5A medium. The solutions were sterilized in 15 ml polypropylene tubes by adding 10% 
chloroform and allowing to sit at 4 oC for 24 hours without shaking. The chloroform 
solution formed a distinct layer at the bottom and mucus solutions were collected without 
disturbing the interface under aseptic conditions. The solutions were aliquoted in 1.5 ml 
polypropylene tubes and stored at -80 oC until use.  
 
3.4.3 Bacteria culture 
Probiotic VSL#3 bacteria were acquired from a commercial source (VSL Pharmaceuticals, 
Inc.) and stored at 4 oC until use. For co-culture experiments, the freeze-dried bacteria were 
aseptically reconstituted in serum- and antibiotic- free McCoy’s 5A medium at a cell 
density of 1010 CFU/ml. Bacterial cells were incubated at 37 oC for 1 hour to recover. After 
1 hour, the cell density was diluted to required cell density by serial dilution.  
 
Wild type Salmonella strain SL1344 was used for live motile bacterial experiments. The 
ΔflhDC SL1344 strain was created using a modified lambda red recombination procedure 
140. SL1344 was transformed with plasmid pkd46 by electroporation. Single colonies were 
inoculated into 50 ml of LB supplemented with 100 μg/ml of carbenicillin and grown at 30 
oC. Once the absorbance at 600 nm (OD600) of the culture reached 0.1, arabinose was 
added to the culture to a final concentration of 20 mM and grown until the OD600 was 
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equal to 0.8. Bacteria were centrifuged at 3000xg for 10 minutes and washed twice with 
nanopure water (Millipore). Bacterial pellet was resuspended in 400 µl of nanopure water. 




ccatggtccatatgaatatc-3’) was mixed with 50 μl of resuspended Salmonella. Bacteria were 
electroporated in a 1 mm cuvette (Fisher Scientific catalog # FB101) with the following 
settings on the electroporation system (BIORAD, GenePulser Xcell): Voltage = 1.8 kV, 
Capacitance = 25 μF, Resistance = 200 Ω, and 5 ms time constant. Primers were purchased 
from Invitrogen, where FOFZ are phosphorothioated nucleotides corresponding to ATAC 
and ZZFF correspond to TTAA. After electroporation, bacteria were recovered in 1 ml of 
LB for 2 hours at 37 oC. The recovery solution was plated on agar plates supplemented 
with kanamycin (50 μg/ml) and incubated at 37 oC overnight. Positive colonies were 
regrown on kanamycin plates overnight at 43 oC in order to eliminate pkd46 from the 
bacteria. Salmonella were transformed with a plasmid encoding for GFP under the control 
of constitutive Plac promoter using electroporation as discussed above. The cultures were 
stored at -80 oC in 25% glycerol solution. 
 
For experiments, frozen stocks of the Salmonella strains were inoculated in LB medium 
and grown overnight at 37 oC. Small amount of overnight culture was inoculated in fresh 
LB medium and allowed to grow to a density of 4 x 108 CFU/ml and used for further 
experiments. To prepare bacteria for transwell co-culture experiments, bacteria culture was 
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subjected to centrifugation at 2500 x g for 10 minutes. The bacterial cell pellet was washed 
three times with PBS by gentle pipetting multiple times and repeating the centrifugation 
step in between. Final pellet was reconstituted in serum- and antibiotic-free McCoy’s 5A 
medium and the required cell density was adjusted by serial dilution.  
 
3.4.4 Epithelial cell seeding in transwell inserts 
For transwell assays, HT-29 cells were detached from culture flasks using trypsin and 
seeded at a density of 105 cells per insert in 3 μm pore size polycarbonate membrane 
transwell inserts (CLS3415, Corning). Inserts were cultured for 7 days in 24 well plates in 
complete McCoy’s medium. The culture medium was changed 24 hours after cell seeding 
and every 48 hours after that. After day 7, the culture medium was aspirated from the 
transwell inserts. The inserts were washed three times with PBS on both the apical and 
basolateral sides. To check for incomplete cell coverage, inserts were filled with 250 μl of 
PBS and the change in liquid level was checked for 5 minutes. The inserts with no change 
in liquid level were used for further experiments. To check for coverage microscopically, 
inserts were seeded with RFP-expressing HT-29 cells. After 7 days of culture, the inserts 
were imaged using EVOS FL Auto imaging system (Life technologies). Images captured 
using a 10x objective were tiled using in-built EVOS software.  
 
3.4.5 Mucus layer formation and cytotoxicity of PSIM on epithelial cells 
To form mucus layers, HT-29 cells were cultured for 7 days in the transwell inserts and 
layered with 100 μl of sterile PSIM (20 mg/ml). Inserts were incubated in a 37 oC 
humidified incubator with 5% CO2 for 12 hours.  
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For testing cytotoxicity of PSIM, HT-29 cells were cultured for 7 days in the transwell 
inserts and washed three times with phosphate buffer saline (PBS). The inserts were 
transferred to a new 24 well plate and 600 μl of serum- and antibiotic-free McCoy’s 5A 
medium was added to the basolateral side. To form the mucus layers, 100 μl of thawed 
PSIM was added to the apical side. For controls, 100 μl of serum- and antibiotic-free 
McCoy’s 5A medium was added to the apical side. The plates were incubated for 24 hours 
at 37 oC. The viability of HT-29 cells after application of the PSIM layer was performed 
using a viability/cytotoxicity assay kit (Cat # L3224, Invitrogen). The transwell inserts 
were transferred to a fresh 24-well plate containing 600 µl of phosphate buffer saline (PBS) 
and rocked gently. The PBS was replaced three times to wash the bottom surface of the 
transwell membrane. Finally, the wash solution was replaced with PBS containing 2 µm 
Calcein AM and 4 µm Ethidium homodimer-1 and incubated for 30 minutes at room 
temperature. Fluorescent images were acquired using Zeiss Spinning Disk Axio Observer 
Z1 microscope (Carl Zeiss) with a C-Apochromat 63x oil immersion objective and Zen 
software. To quantify area coverage, fluorescent images of the stained cells were 
background subtracted and segmented to isolate green (Live) and red (Dead) signal. The 
percent area covered by positive signal from green and red channels was quantified relative 
to the total image area.  
 
To visualize bacteria embedded in the mucus gel, 103 CFU/ml wild type GFP Salmonella 
were mixed in the PSIM solution prior to adding it to transwell inserts covered with HT-
29 cells (as above). After incubation at 37oC for 12 h, the cells and mucus in the inserts 
were fixed using 10% formalin solution in phosphate buffer saline for 20 minutes. The 
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membranes were cut from the inserts and washed in PBS three times. The mucus gel layer 
was separated from the membrane and the cells, transferred onto a coverslip and stained 
with DAPI, which identified the mucus gel under UV light. GFP-expressing Salmonella 
embedded in PSIM gel were imaged using Zeiss Spinning Disk Axio Observer Z1 
microscope (Carl Zeiss). Z-stack images were captured with a 63x oil immersion objective 
at 1 μm height intervals using Zen software. Three-dimensional rendering and image 
processing were performed using Imaris (Bitplane, Belfast, UK).  
 
3.4.6 Immunological response of epithelial and immune cells to PSIM 
For testing immunogenicity of PSIM, HT-29 cells cultured for 7 days in the transwell 
inserts were washed three times with phosphate buffer saline (PBS). The inserts were 
transferred to a new 24 well plate and 600 μl of serum- and antibiotic-free McCoy’s 5A 
medium was added to the basolateral side. Mucus layers were formed by adding 100 μl of 
thawed PSIM (20 mg/ml) to the apical side. For controls, 100 μl of serum- and antibiotic-
free McCoy’s 5A medium was added to the apical side. The plates were incubated for 24 
hours at 37 oC. The media from the basolateral side was collected. Manufacturers protocol 
was followed to quantify human IL-8 (Cat # DY 208) and human TNF-α (Cat # DY 210) 
concentrations using DuoSet ELISA assay kit (R&D Systems). Assays were calibrated to 
the standard curve created for serially diluted IL-8 and TNF-α standard solutions on each 
plate per assay. 
 
Cultured THP-1 cells were washed three times with PBS. After centrifugation, 105 THP-1 
cells were suspended in serum- and antibiotic-free medium (600 μl); seeded into 24 well 
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plates; and 100 μl of thawed PSIM (20 mg/ml) was directly added to the medium. After 24 
hours of incubation at 37 oC, the media were collected and the concentrations of human 
IL-8 and TNF-α were quantified using ELISA assays. 
 
3.4.7 Direct stimulation of HT-29 and THP-1 monocultures 
Twenty-four well tissue culture treated plates were seeded with 105 HT-29 cells per well 
and cultured for 4 days with a media change every day. After 4 days, the cells were washed 
with PBS three times and replaced with 450 μl serum- and antibiotic-free McCoy’s 
medium. To each well, 50 μl of medium was added that contained bacterial endotoxin 
lipopolysaccharide (LPS, 10 μg/ml) from Escherichia coli O55:B5 (Cat # L6529), VSL#3 
(2 x 109 CFU/ml), or Salmonella (2 x 105 CFU/ml). Media alone (50 μl) was added to 
control wells. After 12 hours of incubation at 37 oC, the media were collected. Human IL-
8 and TNF-α concentrations were quantified using ELISA assays.  
 
Using a similar procedure as above, 105 THP-1 cells were suspended in serum- and 
antibiotic-free medium (600 μl); seeded into 24 well plates; and stimulated with 50 μl LPS 
(10 μg/ml), VSL#3 (2 x 109 CFU/ml), and Salmonella (2 x 105 CFU/ml). After 12 hours of 
incubation at 37 oC, the medium was collected and the concentrations of human IL-8 and 
TNF-α were quantified using ELISA assays.  
 
3.4.8 Construction of in vitro mucosal lining model  
Epithelial cells were grown on transwell inserts and checked for coverage and leakage 
using PBS as described above. Mucus layers was formed by adding 100 μl of sterile PSIM 
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(20 mg/ml) and incubating at 37 oC for 12 hours. For controls without mucus, 100 μl serum- 
and antibiotic-free McCoy’s 5A medium was added to the apical side of the inserts. In 
cultures of THP-1 cells, the medium was removed by centrifugation and the cells were 
washed with PBS three times. The cell pellet was suspended in serum- and antibiotic-free 
McCoy’s 5A medium. The medium in the basolateral side of the transwell inserts was 
replaced with 600 μl of THP-1 cell suspension at a density of 105 cells/well.  
 
3.4.9 LPS interaction with in vitro mucosal lining model 
The in vitro mucosal lining model was challenged by adding 50 μl per well LPS (10 μg/ml) 
from Escherichia coli O55:B5 (Cat # L6529) to the apical side of the transwell inserts in 
the presence and absence of a pre-formed PSIM layer. After 24 hours of incubation with 
LPS, the medium from the bottom well was collected for quantification of human IL-8 and 
TNF-α using ELISA.  
 
3.4.10 VSL#3 interaction with in vitro mucosal lining model 
The in vitro mucosal lining model was challenged by adding 50 μl per well of VSL#3 
culture (2 x 109 CFU/ml) to the apical side of the transwell inserts. After 24 hours of 
incubation at 37 oC, the transwell inserts were removed and brightfield images of the 
bottom well containing THP-1 cells were captured using EVOS FL Auto imaging system 
(Life technologies). The contrast of the images was uniformly enhanced. Post-imaging, the 
medium was collected from the bottom well. Half of the medium was used for 
quantification of human IL-8 and human TNF-α with ELISA. The other half was used for 
bacterial quantification by serial dilution, plating on solid agar plates and incubated at 37 
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oC for 24 hours. The colonies were manually counted and converted to CFU based on the 
dilution factor. The THP-1 cell morphology change was manually quantified using ImageJ 
(NIH). Differentiated immune cell were identified as cells having stretched or dendrite-like 
morphology. The number of cells was normalized by the total area of the images.  
 
3.4.11 Salmonella interaction with in vitro mucosal lining model 
The in vitro mucosal lining model was challenged by adding 50 μl per well of GFP-labeled 
Salmonella (2 x 105 CFU/ml) to the apical side of the transwell inserts. After 12 hours of 
incubation at 37 oC, the transwell inserts were removed. Using a plate reader (Synergy H1, 
BioTek Instruments, Inc.), the GFP intensity was quantified in the bottom well plate to 
measure of bacterial cell density. The medium was collected and used for quantification of 
human IL-8 and human TNF-α with ELISA.  
 
3.4.12 Bacterial motility analysis 
Aqueous motility of wild type Salmonella, flagella knockout Salmonella and VSL#3 was 
quantified using fluorescent microscopy. Salmonella strains expressing GFP were grown 
in LB until OD600 was in the range 0.6 – 0.8. A 20 μl droplet containing 107 CFU/ml was 
added onto a glass slide and covered with a coverslip. Fluorescent microscope images were 
captured every 0.141 s for 60 s. Bacterial velocity was analyzed using an automated particle 
tracking program, Trackmate in ImageJ (NIH). The average velocity of all the tracks was 
calculated per sample. To measure the velocity of VSL#3, the bacteria were inoculated in 
serum- and antibiotic-free McCoy’s 5A medium and allowed to recover at 37oC for 1 hour. 
The cells were nuclei stained using Hoechst 33342 (NucBlue, Thermo Fisher, Cat # 
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R37605).  A 20 μl droplet containing 107 CFU/ml was added onto a glass slide and covered 
with a coverslip. Fluorescent microscope images were captured every 0.5 s for 60 s. The 
average velocity was calculated as described above.  
 
3.4.13 Cryopreservation, histological sectioning, and immunofluorescence staining 
To image wild type and flagella knockout Salmonella, bacteria were grown to an OD600 
of 0.8. Twenty μl droplets were applied to glass slides and allowed to dry in a biosafety 
cabinet approximately six hours.  
 
For histological sectioning, the transwell membranes with intact epithelial and mucus 
layers were cut from the inserts and fixed using 10% formalin solution in phosphate buffer 
saline for 20 minutes. Fixed membranes were embedded in optimum cutting temperature 
(OCT) medium and flash frozen in liquid nitrogen. Using a cryostat (CRYOSTAR NX70, 
Thermo Scientific), 30 μm thick cross-sections were cut and collected on ColorMark Plus 
glass slides for imaging. Brightfield images were acquired using an EVOS FL Auto 
imaging system (Life technologies) and the thickness of the mucus layers were measured 
manually using ImageJ (NIH).    
 
For immunofluorescent staining of slides with dried Salmonella, FITC-conjugated anti-
Salmonella antibody (1:200, ab69253, Abcam) was used. Fluorescent images were 
acquired using Zeiss Spinning Disk Axio Observer Z1 microscope (Carl Zeiss) with a C-
Apochromat 63x oil immersion objective and Zen software (Carl Zeiss). For 
immunofluorescent staining of histological cross-sections two antibodies were used: FITC-
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conjugated anti-Salmonella antibody and Alexa Fluor 594 conjugated anti-human CD326 
(EpCAM) antibody (1:200, Cat # 324228, BioLegend). Both samples on glass slides were 
blocked in the blocking solution (1% BSA, 22.52 mg/ml in PBST (PBS + 0.1% Tween20)) 
for 1 hour at room temperature. Slides were incubated with antibodies diluted in 1% BSA 
in PBST for 1 hour at room temperature and washed three times with PBS. Histological 
slices were counter-stained with DAPI (1:10,000, D9542, Sigma Aldrich) to identify cell 
nuclei. Fluorescent images were acquired using Zeiss Spinning Disk Axio Observer Z1 
microscope (Carl Zeiss) with a LD C-Apochromat 40x oil immersion objective and Zen 
software (Carl Zeiss). 
 
The stained histological images were analyzed using ImageJ. To quantify Salmonella 
density in the mucus gel layer, images were tiled to capture from the top of the mucus to 
the bottom of the epithelial layer. Tiled images from three planes deep into the mucus layer 
on the glass slides were captured with 10 μm intervals. These three tiled images were 
projected on to a single plane. Projected images were uniformly segmented to isolate 
bacteria morphologically. The mucus layer height was divided into three regions of equal 
height (T: top; C: center; B: bottom). The amount of Salmonella in each region was 
measured as the percent area with FITC over the total area using ImageJ. 
 
3.4.14 Statistical analysis  
A two-tailed Student’s t-test assuming unequal variances was used for statistical analysis 
of pairwise comparison. One-way ANOVA with Bonferroni post hoc test was used for 
multiple comparisons. All data are presented as a mean ± standard deviation. Differences 
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Figure 3.1. Biocompatibility of epithelial and mucus gel layers formed on a transwell 
membrane. (A) Macroscopic, bottom-view images of the translucent membrane without 
mucus (top left) and the opaque mucus layer after gel formation (bottom left). Tiled 
microscopic image of the transwell membrane with RFP-expressing HT-29 cells covering 
the entire membrane without (top right) and with a mucus layer (bottom right). (B) Side 
view of transwell inserts demonstrating sol (left, top) to gel (left, bottom) transition of PSIM 
at 0 and 12 hours. Microscopic image of a 20 μm thick histological cross-section of the 
transwell membrane covered with HT-29 cell layer (middle) and PSIM gel layer formed 
on top (right). (C) A mucus gel layer formed 12 hours after addition of solubilized PSIM 
(20 mg/ml) and incubation at 37 °C.  (D) Live (Green) and Dead (Red) cell staining of the 
epithelial cell layer on a transwell membrane. (E) Quantified area covered by GFP positive 
and RFP positive signals showed no significant difference with or without mucus (n = 3). 
(F) Confocal microscope image of a DAPI-stained PSIM gel layer (red) with embedded 






Figure 3.2. Immunological response of epithelial and immune cells to PSIM. (A) 
Schematic depiction of the transwell insert placed in 24 multi well plates. HT-29 cells 
(blue) were cultured on the apical side of the transwell membrane and cell culture medium 
was added to the apical (100 μl) and basolateral (600 μl) side of the cells (w/o mucus). 
Reconstituted mucus at 20 mg/ml concentration (brown, 100 μl) layered on top of the 
epithelial cells (w mucus). (B) THP-1 cells cultured in 24 multi well plates and cell culture 
media (w/o mucus, 100 μl) or reconstituted mucus (w/ mucus, 100 μl) added directly to the 
culture medium (600 μl). (C) Mucus increased chemokine (IL-8) secretion from HT-29 
cells (*, P < 0.05; n = 3) and (D) no change in cytokine (TNF-α) secretion. Mucus did not 





Figure 3.3. Stimulation of HT-29 and THP-1 monocultures by LPS and live bacteria. 
(A) IL-8 secretion from HT-29 cells was significantly increased by direct contact with 
Salmonella (**, P < 0.01; n = 3). LPS (10 μg/ml) and VSL#3 caused no significant change 
in IL-8 secretion. (B) LPS and direct contact with VSL#3 and Salmonella caused IL-8 
secretion from THP-1 cells (**, P < 0.01; n = 3). (C) LPS, VSL#3 or Salmonella did not 
cause any TNF-α secretion from HT-29 cells. (D) LPS and direct contact with VSL#3 and 
Salmonella caused TNF-α secretion from THP-1 cells (*, P < 0.05; **, P < 0.01; n = 3). 
(E) Direct contact with VSL#3 caused a change in THP 1 cell morphology (arrows). LPS 
and Salmonella did not change THP-1 morphology. Images were taken 12 hours after 
adding a stimulant. (F) The number of differentiated THP-1 cells per squared millimeter 






Figure 3.4. Barrier function of PSIM layer to molecular diffusion. (A) HT-29 cells 
(blue) on the apical side of the membrane co-cultured with THP-1 cells (red) in 24 multi-
well plates in the absence (top) and presence (bottom) of a PSIM layer (brown). (B,C) The 
concentrations of IL-8 (B) and TNF-α (C) from the co-cultures did not change by adding a 
PSIM layer, significantly increased by adding LPS to the apical side without mucus, and 






Figure 3.5. Barrier function and immune modulation by a PSIM gel layer in response 
to VSL#3. (A) VSL#3 transmigrated across the epithelial layer and caused THP-1 cell 
differentiation identified by elongated morphologies (arrows). Images were taken 24 hours 
after addition of bacteria. (B) The mucus layer significantly reduced the number of 
transmigrated VSL#3 bacteria (*, P < 0.05; n = 3). (C-E) The mucus layer significantly 
reduced the number of differentiated cells per mm2 (C; **, P < 0.01; n = 3), the 
concentration of IL-8 (D; (**, P < 0.01), and the concentration of TNF- α (E; *, P < 0.05) 
in the co-culture. (F) A 20 μm thick histological section (Left) stained with EpCAM (Red) 
and DAPI (Blue). The PSIM gel layer is auto fluorescent (Blue, arrow). Expanded image 
(Right) shows DAPI-stained VSL#3 bacteria embedded at the outer surface of the PSIM 
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gel layer (Arrows). (G) Expanded images of the epithelial layer (white star) showing nuclei 






Figure 3.6. Mucus gel layer is not protective against motile Salmonella. (A) In the 
presence of a mucus layer, the number of transmigrated wild type Salmonella increased (*, 
P < 0.05; n = 3). Mucus decreased the number of transmigrated flagella knockout (k.o.) 
Salmonella (*, P < 0.05). (B) The mean velocity of wild type Salmonella was greater than 
VSL#3 and knockout (ΔflhDC) Salmonella (*, P < 0.05; n=5). (C, D) The concentrations 
of IL-8 (C) and TNF-α (D) in the co-culture in response to wild type and knockout 
Salmonella with and without mucus (*, P < 0.05; n = 3). (E) Fluorescent microscope images 
showing the cell bodies (black arrows) and flagella (white arrow) of the wild type (left) 
and the knockout (right). Only cell bodies are present for the knockout. (F) A histological 
section stained for EPCAM-1 (Red), nuclei (Blue), Salmonella (Green), and the auto 
fluorescent PSIM gel layer (Green, arrow). Depth into the mucus layer is indicated as T: 
top surface, C: center, B: bottom. (G) Bacterial density in the mucus layer as a function of 
depth quantified as the area covered by positive signal from Salmonella stain (**, P < 0.01; 







Figure 3.7. The mucus layer regulates the extent of host-bacterial interactions and the 
resultant immune responses. (A) The mucus layer acts as a barrier to VSL#3 and prevents 
any immune response. (B) In the absence of a mucus barrier, VSL#3 breach the epithelial 
barrier and induce immune responses (TNF-α and IL-8). (C) Despite the presence of a 
mucus layer, Salmonella breach the epithelial barrier and induce chemokine (IL-8) 
responses from epithelial cells and cytokine (TNF-α) and chemokine (IL-8) responses from 
immune cells. (D) In the absence of a mucus layer, Salmonella breach the epithelial barrier 






APPLICATION OF INTESTINAL MUCOSA MODEL TO INVESTIGATE THE 
EFFECT OF PROBIOTICS ON PATHOGENIC SALMONELLA INFECTION 
 
4.1 Introduction 
Intestinal health is highly dependent on the balance between the microbial species present 
in the intestinal tract and the host immune system. Intestinal microbiota plays an important 
role in the development of mucosal immunity, maintenance of homeostasis, and mucosal 
barrier function. An imbalance in the intestinal microbiota also known as dysbiosis is 
linked to several intestinal disorders including inflammatory bowel diseases (IBD) 98-99. 
Dysbiosis can be caused by external factors including abrupt dietary changes, use of 
antibiotics, exposure to pathogens, and medical interventions like chemotherapy. The role 
of dysbiosis in the initiation and severity of enteropathogenic infection is not completely 
understood. The barrier function to pathogens in the intestines is provided by colonization 
resistance from commensal microbiota, the biochemical barrier of mucus, tight junctions 
in the epithelial cell layer, and inflammation induced immunological response from 
resident immune cells 97. The individual, pairwise, and combined interplay of luminal 
bacteria, mucosal barrier, and immune system during enteropathogenic infections are not 
well understood. 
 
Salmonella enterica subsp. enterica serovar Typhimurium (S. typhimurium) is a common 
enteropathogenic strain causing diarrhea, fever, stomach aches, and can often be fatal 117-
118. According to CDC estimates, Salmonella bacteria account for over 1.35 million 
infections, 26,500 hospitalizations, and 420 deaths every year in The United States alone 
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(CDC). The severity of S. typhimurium infections is higher in patients with weakened 
immunity (WHO). A prior exposure to S. typhimurium also correlates positively with 
incidence of chronic conditions in the intestines such as Inflammatory Bowel Diseases 
(IBD) 119-121. Because of the strong link between S. typhimurium infection and host 
immunological response, understanding exact mechanisms involved in these interactions 
will help prevent long-term effects of S. typhimurium infections. The role of commensal 
microbiota and the protective mucus layer in S. typhimurium infection is not fully 
understood.  
 
At the luminal interface, the first point of contact between the ingested pathogens and the 
intestines is the secreted mucus layer. The colonic epithelial cell surface is uniformly 
covered with a mucus layer approximately 800 um thick and minimizes bacterial contact 
with the epithelial cells and tissue resident immune cells 63, 100. Depletion or the improper 
barrier function of the colonic mucus layer is linked to bacterial infiltration 103-105, intestinal 
inflammation and pathology 47, 49, 101-102. In healthy condition, the commensal gut 
microbiota resides in the outer mucus layer closer to the lumen and mucus close to the 
epithelium is devoid of bacteria 63, 100. The microbiota provides competition against 
colonization of ingested pathogens. Dysbiosis of the intestinal microbiota lowers the host 
resistance to pathogenic infections and can lead to chronic conditions like IBD 141. For 
example, dysbiosis associated changes in host metabolism and inflammatory environment 
in the intestines provided a growth advantage to S. typhimurium over the commensal 
microbiota 142. Treatment with antibiotics caused depletion of commensal microbiota 
leading to reduced host resistance to S. typhimurium infection 143.  The near surface 
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swimming of S. typhimurium and the attachment to the mucus layer play a role in its 
infection ability 106, 122-125. S. typhimurium can use flagella-driven motility and taxis to 
access nutrients at the mucosal surface 144-145. How S. typhimurium navigate the colonic 
mucosal interface in presence of dense microbiota residing in the outer mucus layer is 
unknown. A better understanding of the interaction between commensal microbes and S. 
typhimurium at the mucosal interface could help uncover mechanisms of enteric 
salmonellosis. 
 
After crossing the mucus barrier, pathogens encounter the physical barrier created by the 
tight junctions that prevent most bacteria from crossing the epithelial barrier 107-108. Most 
bacteria are detected by binding of common pathogen associated molecular patterns 
(PAMPs)  to receptors present on the epithelial cell surface called the toll-like receptors 
(TLRs) 112-114. Binding of PAMP with TLRs cause activation of downstream pathways like 
NF-κB that regulate secretion of signaling and effector molecules called chemokines and 
cytokines. In the intestines, epithelial cell derived chemokine interleukin-8 (IL-8) after 
detection of bacteria help recruit effector cells like neutrophils to clear the infection 109. In 
case of epithelial barrier breakdown, tissue resident dendritic cells and macrophages detect 
the bacterial PAMPs using TLRs and secrete IL-8 and pro-inflammatory cytokines 
including tumor necrosis factor (TNF-α). TNF-α and IL-8 are pro-inflammatory and 
commonly upregulated in IBD patients 115-116. Identifying the source of these pro-
inflammatory molecules during infection or inflammation can be useful for targeted 
therapy in chronic inflammatory disorders including IBD 146-147.  
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Recently, probiotics have been considered as potential mainstream therapeutics for chronic 
intestinal disorders 148-149. This transition has shown significant success in clinical trials 
and research performed in animals as well as experimental models 150-152. Apart from 
chronic conditions, probiotics have been tested in the treatment of acute pathogenic 
infections both as a treatment as well as a prophylactic. Introducing a defined set of 
microbes into mice provided a strong resistance against S. typhimurium infection and 
reduced pathogenic load in feces 153. For conditions such as recurrent pouchitits, VSL#3 is 
being used as a recommended therapy and is shown effective as a primary prevention 
measure 154. VSL#3 is a commercial probiotic mix containing eight bacterial strains 
(namely Streptococcus thermophilus, Bifidobacterium breve, B. longum, B. infantis, 
Lactobacillus acidophilus, L. plantarum, L. paracasei, and L. delbrueckii subsp. 
Bulgaricus). VSL#3 was shown effective in mitigating pathogenic burden and pro-
inflammatory effects caused by Campylobacter jejuni infections in mice 155. VSL#3 showed 
a protective effect when administered before inducing inflammation (prophylactic) 156 but 
had no healing effect when administered after inducing inflammation (treatment) 157.  
 
Probiotic bacteria induce these protective effects in the host by several mechanisms. These 
mechanisms may include competitive growth inhibition of pathogenic bacteria by nutrient 
sequestration or production of compounds such as bacteriocins that inhibit the growth of 
specific bacteria. It is critical that the probiotics once ingested, effectively colonize the 
gastro-intestinal tract, and accumulate there in significant numbers to provide a tangible 
probiotic effect. There is a direct correlation between longer colonization times and high 
effectiveness of probiotic bacteria 158. Therefore, continual ingestion of probiotics may be 
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required for sustained impact on the host. An understanding of the optimum cell number 
required to impart the probiotic effect would improve the dosage strategies. 
 
Post colonization probiotic bacteria impart several health benefits to the diseased host. For 
example, enhancing epithelial barrier function (ref), modulating epithelial cytokine 
secretion into an anti-inflammatory dominant profile (ref), altering mucus production (ref), 
and modifying the innate and systemic immune responses 159. However, it is not well 
understood if the direct contact of the probiotic bacteria with the epithelial cells is essential 
or they can impart some probiotic effect via secretory mechanisms. Since mucus layer coats 
the epithelium, it is critical to evaluate the role of mucus barrier in mediating the effects of 
probiotics on the host. The complexity of the intestinal microenvironment with 
continuously evolving luminal environment, diverse microbiota and high prevalence of 
immune cells make it difficult to parse out bacteria-mucus-host cell interactions in vivo. 
In vitro investigations into the bacteria-epithelial interactions are limited due to the poor 
mucus secretion and non-uniform coverage in the cellular models commonly used as 
intestinal epithelium. Recent advances using primary colonic cells combined with air-
liquid interface and gut-on-a-chip microfluidic culture methods achieved significantly 
thicker mucus layer compared to cell lines 133-134. For non-mucus secreting cell line based 
models, porcine mucus is a good alternative for rarely available human mucus 16-17, 34-35. 
We have developed a method to extract porcine small intestinal mucus (PSIM) that retained 
the functions of native intestinal mucus 138. Subsequently, we developed an intestinal 
mucosa model including a mucus gel matrix on top of the epithelium that enabled co-
culture with live bacteria and immune cells 160. The intestinal mucosa model consists of all 
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three components (structural mucus gel matrix, epithelial layer, and innate immune cells) 
that captures the essential complexities of the mucosal layer in the intestine.  
 
Here, we use the intestinal mucosa model 160 to quantify the role of mucus and epithelial 
barrier in regulating the host innate immune responses to probiotic and pathogenic bacteria. 
In case of a pathogenic infection, investigating a range of an effective ratio of probiotic to 
pathogen that could prevent the growth of the pathogen can help dictate the dosage and the 
duration of probiotic intake. To investigate if probiotic mixture VSL#3 can prevent 
pathogenic S. typhimurium growth, different mixing ratios were co-cultured and S. 
typhimurium growth was quantified using fluorescent spectroscopy. The co-cultures were 
added to independently cultured epithelial and innate immune cells to quantify the amount 
of pro-inflammatory chemokine and cytokine by enzyme-linked immunosorbent assay 
(ELISA). The intestinal mucosa model was used to test the hypothesis that S. typhimurium 
could escape any inhibitory or anti-inflammatory effects exerted by VSL#3 in the presence 
of mucus. In the mucosa model, a selectively permeable mucus gel matrix formed closely 
attached to the epithelium that enabled the investigation into the role of mucus barrier on 
the interactions of cocultured bacteria with epithelial cells. Additionally, the mucosa model 
provided easy access to the culture medium for quantification of immunological responses 
from human epithelial and immune cell cocultures. Bacterial penetration across the 
epithelial barrier was quantified using fluorescent confocal microscopy of the transwell 
membranes that support the epithelial layers. Mechanistic understanding of the interactions 
of pathogenic and probiotic bacteria with mucus, epithelial cell layer and immune cells 
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independently as well as in co-culture will help improve the probiotic formulations and 
dosage strategies for intestinal diseases.  
 
4.2 Results 
4.2.1 VSL#3 suppresses the growth of S. typhimurium in co-culture.  
In co-culture, the growth of S. typhimurium was affected by the initial density of VSL#3 
(Figure 1). When S. typhimurium were cultured alone, the time to maximum density 
increased with decreasing initial density (Figure 1B, top left). At initial densities of 103,102 
and 10, the time to maximum density was 6.8, 9.2 and 11.1 h, respectively. These times to 
maximum density did not change with the addition of VSL#3 (Figure 4.1B).  
 
At an equal seeding density, VSL#3 had almost no effect on S. typhimurium growth (Figure 
1B, top right, circles) compared to S. typhimurium alone (Figure 4.1B, top left). When the 
initial density of VSL#3 was 102 times that of S. typhimurium, the maximum density 
reduced (Figure 4.1B, bottom left, circles). The greatest effect on growth was when the 
initial density of VSL#3 was 104 times the density of S. typhimurium (Figure 4.1B, bottom 
right). This condition almost completely blocked the growth of S. typhimurium. At the 
point of maximum density (8 h for an initial S. typhimurium density of 103), the Salmonella 
density was reduced to almost zero (**, P < 0.01; Figure 4.1C). The density at the endpoint 




The growth of S. typhimurium was dependent on both the initial density ratio and the 
absolute initial density. At a density ratio of 104 and low densities (10 and 105 CFU/well 
of S. typhimurium and VSL#3, respectively), there was considerable growth (Figure 4.1B, 
bottom left, squares). At the same density ratio but higher overall densities (103 and 107 
CFU/well), growth was almost completely suppressed (Figure 4.1B, bottom right, circles).  
The different growth responses at these conditions represent four physiological conditions 
in the intestinal lumen. (1) All VSL#3 (107 CFU/well; termed V7) represents healthy 
commensal microbiota with no pathogens. (2) All S. typhimurium (103 CFU/well; termed 
S3) represents a high pathogen load with depleted commensal microbiota. (3) Equal density 
(103 VSL#3 and S. typhimurium CFU/well; termed V3S3) represents a high pathogen load 
with commensal dysbiosis. (4) Mostly VSL#3 (107 CFU/well VSL#3 and 103 CFU/well S. 
typhimurium; termed V7S3) represents a low pathogen load with healthy commensal 
microbiota. These four conditions were used for most of the subsequent experiments.   
 
4.2.2 Mucus gel matrix using PSIM match the colonic mucus layer in vivo. 
The native mucus barrier is impenetrable to bacteria-sized beads. The mucus gel matrix 
formed at different concentration of PSIM (Figure 4.2A) and prevented the bacteria-sized 
polystyrene beads are from coming in contact with the epithelial cells (Figure 4.2B). The 
mucus gel matrix is impenetrable to bacteria sized beads. At a PSIM concentration of 0.5 
mg/ml, fluorescent bacteria-sized beads were in direct contact with the epithelial cell layer. 
Increasing the PSIM concentration to 1 mg/ml caused a separation of 40.85 ± 0.7 μm. 
Further increase in the PSIM concentration to 2.5 mg/ml caused a separation greater than 
100 μm, since the beads were not present in the field of view. A PSIM concentration of 20 
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mg/ml matches the overall thickness of the colonic mucus layer in vivo (Figure 4.2C). The 
mucus gel matrix formed using solubilized PSIM is structurally stable, closely attached to 
the epithelium, and qualitatively resembles the mucus layer structure in vivo (Figure 4.2D). 
 
4.2.3 Presence of VSL#3 alters the host immune responses to S. typhimurium.  
VSL#3 affects the S. typhimurium induced pro-inflammatory chemokine and cytokine 
secretion from human epithelial and immune cell co-culture. Bacteria were co-cultured in 
the mucosal barrier platform to quantify the effect of VSL#3, S. typhimurium and the mixed 
bacterial cocultures on the epithelial and immune cell responses (Figure 4.3A). The co-
cultures were performed with or without mucus barrier added on top of epithelial cell layer. 
VSL#3 alone did not induce a chemokine (IL-8) response. Also, IL-8 response was 
significantly higher in presence of S. typhimurium alone compared to VSL#3 (**; P < 0.01, 
Figure 4.3B). Addition of mucus caused a small increase in IL-8 in presence of S. 
typhimurium. When VSL#3 and S. typhimurium mixed at equal proportion were added, IL-
8 response further increased significantly in the absence of mucus (**; P < 0.01, Figure 
4.3B). Similar addition of the bacteria mixed in equal proportions and in presence of mucus 
caused a 2-fold increase in IL-8 compared to the absence of mucus. Compared to S. 
typhimurium alone, equal density mixture of VSL#3 and S. typhimurium caused an increase 
of 2.6-fold in IL-8 when mucus is present. In the absence of mucus this increase is 
significantly lower (1.8-fold). Increasing the ratio of VSL#3:S. typhimurium to 104:1 
reduced the IL-8 amount 10-fold in the absence of mucus but only 3-fold reduction was 
seen in the presence of mucus. In the absence of mucus, the IL-8 amount under this 
condition was equal to the amount of IL-8 induced by VSL#3 alone. These results suggest 
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that VSL#3 at high density ratio of 104:1 significantly suppress the IL-8 response and this 
anti-inflammatory effect is stronger in the absence of mucus barrier. Similar to IL-8, co-
culture of VSL#3 alone did not cause TNF-α production in the mucosal barrier platform. 
Addition of S. typhimurium alone caused a 6-fold increase in TNF-α in the absence of 
mucus and a 10-fold increase in the presence of mucus (**; P < 0.01, Figure 4.3C) when 
compared to VSL#3 alone. Presence of mucus caused a 2-fold increase in TNF-α caused by 
S. typhimurium alone. Adding VSL#3 and S. typhimurium in equal ratio caused a significant 
increase in TNF-α without mucus but did not have any effect in presence of mucus. 
Increasing the ratio of VSL#3:S. typhimurium to 104:1 caused a significant reduction in 
TNF-α. As seen with IL-8 response, VSL#3 completely suppressed the TNF-α production 
in the absence of mucus. The presence of mucus caused a 2-fold increase in the TNF-α 
secretion suggesting that presence of mucus promotes a pro-inflammatory response in 
presence of S. typhimurium.  
 
4.2.4 More S. typhimurium cross the epithelial layer in presence of the mucus gel 
matrix.   
Higher number of S. typhimurium crossed the epithelial layer in presence mucus gel matrix. 
Fluorescent confocal microscopy was used to quantify the number of S. typhimurium that 
have crossed the epithelial layer (Figure 4.4A). In presence of mucus gel matrix, addition 
of S. typhimurium alone increased the number of bacteria by 2.5-fold compared to epithelial 
layer only (*; P < 0.05, Figure 4.4B). Compared to S. typhimurium alone, equal density 
mixture of VSL#3 and S. typhimurium caused an increase of 4-fold in IL-8 when mucus is 
present (**; P < 0.01, Figure 4B). In the absence of mucus this increase in the number of 
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S. typhimurium is significantly lower (1.9-fold). Increasing the ratio of VSL#3:S. 
typhimurium to 104:1 prevented S. typhimurium completely and no bacteria were found on 
the membrane in the absence of mucus. On the other hand, presence of mucus significantly 
increased the number of S. typhimurium present on the transwell membrane compared to 
without mucus (*; P < 0.05, Figure 4.4B). The results show that increase in the cytokine 
and chemokine response is linked to higher migration of S. typhimurium across the mucosal 
barrier. 
 
4.2.5 Epithelial and immune cell responses vary depending on the bacterial stimuli.  
To parse out the individual contributions of epithelial and immune cells to the responses 
discussed above, bacteria were co-cultured with individual cultures of HT-29 and THP-1 
cells (Figure 4.5A). Bacteria were introduced to the cultures in the same schemes as 
discussed with the mucosal barrier model. VSL#3 alone did not cause IL-8 secretion from 
the HT-29 cells. S. typhimurium alone caused a 17-fold increase in IL-8 secretion from HT-
29 cells (**; P < 0.01, Figure 4.5B). Adding VSL#3 and S. typhimurium in equal ratio 
increased the IL-8 secretion 43-fold compared to VSL#3 alone. Further increasing the ratio 
of VSL#3:S. typhimurium to 104:1 caused a significant reduction as the level of IL-8 was 
similar to the level observed with VSL#3 alone. HT-29 cells did not secrete TNF-α in 
response to any configuration of bacteria (Figure 4.5C). Compared to HT-29 cells, a 
reverse trend in IL-8 secretion from THP-1 cells was observed. VSL#3 alone caused a 
significantly higher IL-8 secretion from THP-1 cells compared to S. typhimurium or any 
combination of VSL#3 and S. typhimurium mixtures. S. typhimurium alone caused a 3-fold 
reduction in IL-8 secretion from THP-1 cells compared to VSL#3 alone. Equal ratio of 
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VSL#3 and S. typhimurium had a similar effect, and there was no difference compared to 
S. typhimurium alone. Increasing the ratio of VSL#3:S. typhimurium to 104:1 caused a 
significant increase in IL-8 secretion from THP-1 cells compared to VSL#3 alone (*; P < 
0.05, Figure 4.5D). Similarly, the TNF-α production from THP-1 cells was highest in 
response to VSL#3 alone. Presence of S. typhimurium significantly suppressed the TNF-α 
response from THP-1 cells (**; P < 0.01, Figure 4.5E). 
 
4.3 Discussion 
In this study, we investigated the role of dysbiosis in pathogenic infection by coculturing 
pathogenic S. typhimurium SL1344 with a mixture of eight bacteria (VSL#3). We found 
that relative ratios of VSL#3 and S. typhimurium in the lumen dictate the effectiveness of 
VSL#3 in suppressing pathogenic infection and host inflammatory response. VSL#3 was 
most effective in suppressing S. typhimurium growth when the number of VSL#3 exceeded 
that of S. typhimurium by a factor of 104 or more. The bacteria present in VSL#3 represent 
the members of commensal microbiota in healthy humans. The competitive growth 
inhibition of S. typhimurium by VSL#3 present at high numbers effectively demonstrates 
how the species of commensal microbiota provide resistance to pathogens in vivo.  
 
Dysbiosis of the intestinal microbiota lowers the host resistance to pathogenic colonization 
and infections. Indeed, when the number of VSL#3 and S. typhimurium in the coculture 
were equal, no significant reduction in S. typhimurium growth was seen. Another factor 
that affected S. typhimurium growth was the initial number of S. typhimurium irrespective 
of the VSL#3 to S. typhimurium ratio. The results suggest that if a sufficient number of S. 
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typhimurium are present at the site of infection, the commensal microbiota may not be 
effective in preventing infection. Therefore, the factors including ingestion in large 
numbers through food or an imbalance in the commensal microbiota provide a growth 
advantage to S. typhimurium and may promote its infection ability. For example, such 
imbalance in the commensal microbiota may be induced by broad-spectrum antibiotic 
treatment which leaves the host susceptible to virulent pathogens like S. typhimurium 143. 
 
The relative ratios of VSL#3 and S. typhimurium also dictated the pro-inflammatory 
chemokine (IL-8) response from human epithelial cells. The reduction in IL-8 was most 
effective at the ratio of 104:1, when the growth of S. typhimurium was completely 
suppressed suggesting that inhibition of S. typhimurium growth is key for reducing 
inflammation. A coculture of S. typhimurium and VSL#3 at equal numbers significantly 
increased IL-8 secretion from epithelial cells compared to S. typhimurium alone. Since 
VSL#3 alone did not induce any inflammatory response in epithelial cells, this result 
indicates some communication between the bacterial species that leads to a strong pro-
inflammatory response induced by S. typhimurium. A possible explanation is that with 
equal numbers, VSL#3 does not inhibit S. typhimurium growth effectively but contributes 
to nutrient deprivation. Nutrient deprived conditions can induce a switch to a hypervirulent 
phenotype in S. typhimurium 161. Overall, these results show that VSL#3 is protective only 
when the ratio of VSL#3 to S. typhimurium is in the order of 104 or higher but can contribute 
to depletion of nutrients and therefore a more robust S. typhimurium infection when the 
ratio is close to one. Clinically, this could mean that an insufficient dosage of VSL#3 can 




We have developed an intestinal mucosa model that consists of all three components 
(structural mucus gel matrix, epithelial layer, and innate immune cells) required to capture 
the essential complexities of the mucosal layer in the intestine. The mucus gel matrix not 
only matched the thickness and structure of colonic mucus layer but is also impenetrable 
to bacteria sized beads (Figure. 4.2) and non-motile bacteria 160.  The intestinal mucosa 
model was used to confirm the hypothesis that mucus gel matrix helps S. typhimurium 
escape the competitive growth inhibition and anti-inflammatory effects exerted by VSL#3. 
In the absence of mucus, S. typhimurium induced a strong IL-8 and TNF-α secretion which 
was significantly suppressed by addition of 104 times higher number of VSL#3. However, 
in the presence of mucus, VSL#3 failed to suppress S. typhimurium induced IL-8 and TNF-
α secretion. Combined, these results show that the protective effect of VSL#3 in limiting S. 
typhimurium growth and suppressing inflammation is limited to the luminal interface of 
mucus. We have shown that the non-motile bacteria in VSL#3 does not penetrate the mucus 
gel matrix and accumulate at the mucus interface 160. On the contrary, the presence of 
mucus increased the penetration of motile S. typhimurium across the intestinal barrier. The 
increase in transmigration of S. typhimurium in the presence of mucus is flagella dependent 
since the strain of S. typhimurium with a flagella-knockout gene did not penetrate the 
intestinal barrier. Therefore, the limited migration of VSL#3 and preferential taxis of S. 





A similar scenario happens in vivo where most of the commensal microbiota in the colon 
reside in the outer mucus layer closer to the lumen and the mucus close to the epithelium 
is devoid of bacteria. The mucus layer and commensal microbiota combined must therefore 
provide protection from pathogens. Despite the presence of commensal microbiota in the 
outer mucus layer and the strong barrier effect of the inner mucus layer, S. typhimurium is 
highly successful at infecting the underlying epithelium. This suggests that in the intestinal 
mucosa of a host, motile S. typhimurium use the mucus layer to its advantage and escape 
competition from the microbiota. In this regard, the use of ‘motile probiotics’ that can 
effectively navigate the mucus layer and compete with motile pathogens can be explored. 
An example of a motile probiotic is Escherichia coli strain Nissle 1917 (EcN) that possess 
flagella162, is antagonistic against pathogens163, has been safely administered in humans 164-
165, and can be genetically engineered to develop safe and effective therapy against motile 
enteric pathogens 166. These motile probiotics would not only cause growth inhibition at 
the luminal mucus interface but also compete for nutrients and antagonize the pathogens 
throughout the mucus gel matrix. Using the intestinal mucosa model, future coculture 
studies can be performed to systematically investigate the utility of motile probiotics in 
preventing infections caused by pathogens that overcome the mucus barrier. 
 
Clinical use of probiotics targeted towards protection against pathogen invasion and 
intestinal inflammation is on the rise 167. In vivo studies have shown mixed results for 
protective effects of VSL#3 on mucosal barrier healing. VSL#3 showed a protective effect 
when administered before inducing inflammation (prophylactic) 156 but had no healing 
effect when administered after inducing inflammation (treatment) 157. The results presented 
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here show that the prophylactic effect of VSL#3 against S. typhimurium infection can be 
negated in the presence of mucus. Additionally, clinical benefit can be achieved by a high 
dosage routine of VSL#3 enabling robust colonization and growth in the intestines to 
outnumber the pathogens and prevent pathogenic growth. This strategy can be most 
effective in patients with pre-existing intestinal conditions like Ulcerative colitis since the 
mucus layer is either very thin or absent in the lesion areas.   
 
With the rise in antibiotic resistant pathogens due to rampant use of antibiotics, the use of 
probiotics can be a successful alternative in preventing food poisoning from common 
pathogens. This study provides preliminary proof of the use of VSL#3 as a prophylactic 
and could guide the dosing strategies for its use in preventing conditions like traveler’s 
diarrhea. About 55% of people traveling from developed countries to developing countries 
develop acute diarrhea 168-169. Therefore, development of general prophylactic treatments 
against diarrhea causing pathogens in the form of probiotics are required. In this regard, 
the intestinal mucosa model presented here served as an effective tool to test probiotic 
efficacy against S. typhimurium infection. The modular nature of this model allowed us to 
parse out individual and synergistic interactions of bacteria amongst themselves and with 
the host mucosal interface. The platform is amenable to most common characterization 
methods including histology, immunostaining, confocal microscopy, and immunological 
assays like ELSIA. Most results presented here are only feasible by combining the barrier 
components of the mucosal layer including mucus gel matrix, epithelial layer, and innate 
immune cells. A mechanistic understanding of how all these components interact in the 
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intestinal milieu will help advance therapeutic discovery and treatment for common 
intestinal infections and chronic diseases like IBD. 
  
4.4 Materials and Methods 
All chemicals and supplies were purchased from Fisher Scientific and Sigma Aldrich 
unless otherwise specified. 
 
4.4.1 Mammalian cell culture 
HT-29 (ATCC, HTB-38) adherent cells were cultured in McCoy’s 5A medium (Sigma 
Aldrich) supplemented with 2.2 g/L sodium bicarbonate. THP-1 (ATCC, TIB-202) 
suspension cells were cultured in RPMI-1640 medium (containing 0.05 mM β-
Mercaptoethanol). All media were supplemented with 10% fetal bovine serum (FBS) and 
1% penicillin/streptomycin and referred to as complete medium in the methods. Cells were 
maintained in a 37 oC humidified incubator with 5% CO2. 
 
4.4.2 Solubilized PSIM preparation 
PSIM was extracted, sterilized, and prepared for cell culture as described before 138, 160. 
Briefly, intact small intestine tubules were cut into 2-meter lengths and rinsed with water 
to eliminate food particles from the lumen. The tubules were drained gently, and the lumen 
was filled with 350 ml of 0.01 M NaOH. The ends of the tubules were tied and incubated 
for 24 hours at 4 oC. After incubation, the solubilized material was drained by squeezing 
and collected. The extract was subjected to centrifugation at 20,000 x g (Thermo Scientific) 
at 4 oC for 2 hours to remove insoluble debris. The supernatant was collected without 
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disturbing the precipitate. The clear supernatant was subjected to sol-gel transition by 
adjusting the pH to 4 using 2 M HCl. The aggregates formed at pH 4 were subjected to 
centrifugation at 200 x g for 15 minutes and resolubilized in sterile DI water by adjusting 
the pH value to 8. The solution was passed through a 40 μm strainer and subjected to 
dialysis using a membrane with molecular size cut-off equal to 14 kDa.  The dialyzed 
mucus extract was sterilized by adding 1% (v/v) chloroform under constant stirring at 4 ºC 
for 72 hours. The solution (30 ml aliquots) was transferred to 50 ml conical polypropylene 
tubes, frozen to -80 oC, and freeze dried (Labconco Freezone 2.5 L freeze dry system). The 
freeze-dried mucus was reconstituted aseptically in serum- and antibiotic-free McCoy’s 
5A medium. The solutions were sterilized in 15 ml polypropylene tubes by adding 10% 
chloroform and allowing to sit at 4 oC for 24 hours without shaking. The chloroform 
solution formed a distinct layer at the bottom and mucus solutions were collected without 
disturbing the interface under aseptic conditions. The solutions were aliquoted in 1.5 ml 
polypropylene tubes and stored at -80 oC until use.  
 
4.4.3 VSL#3 and S. typhimurium bacteria culture 
Probiotic VSL#3 bacteria were acquired from a commercial source (VSL Pharmaceuticals, 
Inc.) and stored at 4 oC until use. For co-culture experiments, the freeze-dried bacteria were 
aseptically reconstituted in serum- and antibiotic- free McCoy’s 5A medium at a cell 
density of 1010 CFU/ml. Bacterial cells were incubated at 37 oC for 1 hour to recover. After 




Wild type S. typhimurium strain SL1344 was used for live motile bacterial experiments. 
For experiments, frozen stocks of the S. typhimurium strains were inoculated in LB medium 
and grown overnight at 37 oC. Small amount of overnight culture was inoculated in fresh 
LB medium and allowed to grow to a density of 4 x 108 CFU/ml and used for further 
experiments. To prepare bacteria for transwell co-culture experiments, bacteria culture was 
subjected to centrifugation at 2500 x g for 10 minutes. The bacterial cell pellet was washed 
three times with PBS by gentle pipetting multiple times and repeating the centrifugation 
step in between. Final pellet was reconstituted in serum- and antibiotic-free McCoy’s 5A 
medium and the required cell density was adjusted by serial dilution.  
 
4.4.4 HT-29 cell seeding and culture in transwells 
For transwell assays, HT-29 cells were detached from culture flasks using trypsin and 
seeded at a density of 105 cells per insert in 3 μm pore size polycarbonate membrane 
transwell inserts (CLS3415, Corning). Inserts were cultured for 7 days in 24 well plates in 
complete McCoy’s medium. The culture medium was changed 24 hours after cell seeding 
and every 48 hours after that. After day 7, the culture medium was aspirated from the 
transwell inserts. The inserts were washed three times with PBS on both the apical and 
basolateral sides. To check for incomplete cell coverage, inserts were filled with 250 μl of 
PBS and the change in liquid level was checked for 5 minutes. The inserts with no change 
in liquid level were used for further experiments. To check for coverage microscopically, 
inserts were seeded with RFP-expressing HT-29 cells. After 7 days of culture, the inserts 
were imaged using EVOS FL Auto imaging system (Life technologies). Images captured 
using a 10x objective were tiled using in-built EVOS software.  
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4.4.5 Mucus gel matrix formation on HT-29 cell surface and mucosal barrier platform 
setup 
Epithelial cells were grown on transwell inserts and checked for coverage and leakage 
using PBS as described above. Mucus layers was formed by adding 100 μl of sterile PSIM 
(20 mg/ml) and incubating at 37 oC for 12 hours. For controls without mucus, 100 μl serum- 
and antibiotic-free McCoy’s 5A medium was added to the apical side of the inserts. In 
cultures of THP-1 cells, the medium was removed by centrifugation and the cells were 
washed with PBS three times. The cell pellet was suspended in serum- and antibiotic-free 
McCoy’s 5A medium. The medium in the basolateral side of the transwell inserts was 
replaced with 600 μl of THP-1 cell suspension at a density of 105 cells/well. Manufacturers 
protocol was followed to quantify human IL-8 (Cat # DY 208) and human TNF-α (Cat # 
DY 210) concentrations using DuoSet ELISA assay kit (R&D Systems). Assays were 
calibrated to the standard curve created for serially diluted IL-8 and TNF-α standard 
solutions on each plate per assay.  
 
4.4.6 Stimulation of HT-29 and THP-1 monocultures with VSL#3 and S. typhimurium  
Twenty-four well tissue culture treated plates were seeded with 105 HT-29 cells per well 
and cultured for 4 days with a media change every day. After 4 days, the cells were washed 
with PBS three times and replaced with 450 μl serum- and antibiotic-free McCoy’s 
medium. To each well, 50 μl of medium was added that contained bacterial endotoxin 
lipopolysaccharide (LPS, 10 μg/ml) from Escherichia coli O55:B5 (Cat # L6529), VSL#3 
(2 x 109 CFU/ml), or S. typhimurium (2 x 105 CFU/ml). Media alone (50 μl) was added to 
control wells. After 12 hours of incubation at 37 oC, the media were collected from three 
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independent experimental conditions. Human IL-8 and TNF-α concentrations were 
quantified using ELISA assays.  
 
Using a similar procedure as above, 105 THP-1 cells were suspended in serum- and 
antibiotic-free medium (600 μl); seeded into 24 well plates; and stimulated with 50 μl LPS 
(10 μg/ml), VSL#3 (2 x 109 CFU/ml), and S. typhimurium (2 x 105 CFU/ml). After 12 
hours of incubation at 37 oC, the medium was collected and the concentrations of human 
IL-8 and TNF-α were quantified using ELISA assays. Results from three independent 
experiments were used analysis. 
 
4.4.7 VSL#3 interaction with in vitro mucosal lining model 
The in vitro mucosal lining model was challenged by adding 50 μl per well of VSL#3 
culture (2 x 109 CFU/ml) to the apical side of the transwell inserts. After 12 hours of 
incubation at 37 oC, the transwell inserts were removed and brightfield images of the 
bottom well containing THP-1 cells were captured using EVOS FL Auto imaging system 
(Life technologies). The contrast of the images was uniformly enhanced. Post-imaging, the 
medium was collected from the bottom well. Half of the medium was used for 
quantification of human IL-8 and human TNF-α with ELISA. Data was analyzed for three 
independent experiments.  
 
4.4.8 S. typhimurium interaction with mucosal barrier model 
The in vitro mucosal lining model was challenged by adding 50 μl per well of GFP-labeled 
S. typhimurium (2 x 105 CFU/ml) to the apical side of the transwell inserts. After 12 hours 
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of incubation at 37 oC, the transwell inserts were removed. The medium was collected and 
used for quantification of human IL-8 and human TNF-α with ELISA. Measurements and 
analysis were performed for three independently conducted experiments. 
 
4.4.9 VSL#3 and S. typhimurium coculture interaction with mucosal barrier model 
The in vitro mucosal lining model was challenged by adding 50 μl per well of GFP-labeled 
S. typhimurium and untagged VSL#3 at specified density ratios to the apical side of the 
transwell inserts. After 12 hours of incubation at 37 oC, the transwell inserts were removed. 
The medium was collected and used for quantification of human IL-8 and human TNF-α 
with ELISA. Measurements and analysis were performed for three independently 
conducted experiments. 
 
4.4.10 Cryopreservation, sectioning, and immunohistochemistry 
To image and wild type and flagella knockout S. typhimurium, bacteria were grown to an 
OD600 of 0.8. Twenty μl droplets were applied to glass slides and allowed to dry in a 
biosafety cabinet for approximately six hours.  
 
For histological sectioning, the transwell membranes with intact epithelial and mucus 
layers were cut from the inserts and fixed using 10% formalin solution in phosphate buffer 
saline for 20 minutes. Fixed membranes were embedded in optimum cutting temperature 
(OCT) medium and flash frozen in liquid nitrogen. Using a cryostat (CRYOSTAR NX70, 
Thermo Scientific), 30 μm thick cross-sections were cut and collected on Color Mark Plus 
glass slides for imaging. Brightfield images were acquired using an EVOS FL Auto 
 
97 
imaging system (Life technologies) and the thickness of the mucus layers were measured 
manually using ImageJ (NIH). Images from three independent samples were used for 
measuring the thickness. 
 
For immunofluorescent staining of histological cross-sections two antibodies were used: 
FITC-conjugated anti-S. typhimurium antibody and Alexa Fluor 594 conjugated anti-
human CD326 (EpCAM) antibody (1:200, Cat # 324228, Bio Legend). Sections on the 
glass slides were blocked in the blocking solution (1% BSA, 22.52 mg/ml in PBST (PBS 
+ 0.1% Tween20)) for 1 hour at room temperature. Slides were incubated with antibodies 
diluted in 1% BSA in PBST for 1 hour at room temperature and washed three times with 
PBS. Histological slices were counter-stained with DAPI (1:10,000, D9542, Sigma 
Aldrich) to identify cell nuclei. Fluorescent images were acquired using Zeiss Spinning 
Disk Axio Observer Z1 microscope (Carl Zeiss) with a LD C-Apochromat 40x oil 
immersion objective and Zen software (Carl Zeiss). 
 
The stained histological images were analyzed using ImageJ. To quantify S. typhimurium 
density in the mucus gel layer, images were tiled to capture from the top of the mucus to 
the bottom of the epithelial layer. Tiled images from three planes deep into the mucus layer 
on the glass slides were captured with 10 μm intervals. These three tiled images were 
projected on to a single plane. Projected images were uniformly segmented to isolate 
bacteria morphologically. The mucus layer height was divided into three regions of equal 
height (T: top; C: center; B: bottom). Images were collected from three independent 
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samples. The amount of S. typhimurium in each region was measured as the percent area 
with FITC over the total area using ImageJ. 
 
4.4.11 Statistical analysis  
A two-tailed Student’s t-test assuming unequal variances was used for statistical analysis 
of pairwise comparison. One-way ANOVA with Tukey post hoc test was used for multiple 
comparisons. All data are presented as a mean ± standard deviation for three or more 
independent experimental conditions. Differences were considered significant at P < 0.05, 








Figure 4.1. S. typhimurium growth in co-culture with VSL#3. (A) Schematic of the co-
culture of untagged VSL#3 and GFP-expressing S. typhimurium in 96 multi-well plates and 
quantification of growth by fluorescence spectroscopy in a multi-well plate reader. (B) 
Growth curves of S. typhimurium with changing initial seeding density. (C) Cell density 
(RFU) at 8 hours where the peak was observed for all growth curves (**, P < 0.01; n = 3). 
(D) Cell density (RFU) at the end point of 12 hours used for all the co-culture studies with 
human epithelial and immune cells (**, P < 0.01; n = 3). (S, V denotes and S. typhimurium, 






Figure 4.2. Mucus gel layer formation matching the thickness of colonic mucus. (A) 
Schematic of the mucus gel layer formation on top of HT-29 epithelial cells growing on 
transwell membrane. A 100 μl of PSIM at known concentrations were added on the apical 
side of the transwell inserts containing the HT-29 cell layers and cultured for 12 hours at 
37oC to form the mucus gel matrix. (B) Confocal images of red fluorescent polystyrene 
beads added after mucus gel layer formation on HT-29 cells (Blue) at different PSIM 
concentration 0.5, 1, and 2 mg/ml. Top row shows the x-y projection and the bottom row 
shows the z-projection. Dotted line represents the plane of highest intensity of the 
fluorescent beads.  (C) Table containing the average thicknesses of the mucus gel layer 
using PSIM160 at different concentrations compared with the average mucus layer thickness 
of colonic mucus layer in vivo58. (D) Mucus gel layer formed at PSIM concentration of 20 
mg/ml matched the thickness and structure of the colonic mucus layer in vivo. Dotted line 





Figure 4.3. Chemokine (IL-8) and cytokine (TNF-α) levels in the mucosal barrier 
model. (A) The infection scheme for introducing VSL#3 and S. typhimurium individually 
and cocultured into the mucosal barrier model with or without mucus gel matrix. IL-8 and 
TNF-α were quantified in the media collected from the basolateral compartment after 12 
hours of culture. Notations denote V7 = 107 CFU/insert of VSL#3, S3 = 103 CFU/insert, 
V3S3 =  103 CFU/insert of VSL#3 + 103 CFU/insert of S. typhimurium, and V7S3 = 107 
CFU/insert of VSL#3 + 103 CFU/insert of S. typhimurium added apically (100 μl) and 
cultured for 12 hours. Concentration of (B) IL-8 and (C) TNF-α from the mucosal barrier 
platform in response to stimulation with different bacterial cell densities after 12 hours of 





Figure 4.4. Quantification of S. typhimurium crossing the epithelial barrier. (A) S. 
typhimurium (Green) that have crossed the epithelial (Blue) barrier visualized using 
confocal microscopy. Black arrows indicate the pores in the transwell membrane and white 
arrows indicate S. typhimurium. (B) The number of S. typhimurium quantified by manual 





Figure 4.5. Chemokine (IL-8) and cytokine (TNF-α) levels from stimulated epithelial 
(HT-29) and immune (THP-1) cells. (A) The infection scheme for introducing VSL#3 and 
S. typhimurium individually and cocultured into 24 well plates with adherent HT-29 cells 
and suspended THP-1 cells. IL-8 and TNF-α were quantified in the media collected after 
12 hours of culture.  Concentration of (B) IL-8 and (C) TNF-α from the HT-29 cells in 
response to stimulation with different bacterial cell densities (*, P < 0.05; **, P < 0.01; n 
= 3). Concentration of (D) IL-8 and (E) TNF-α from the THP-1 cells in response to 




Figure 4.6. S. typhimurium utilize the mucus barrier to escape competitive growth 
inhibition from commensal bacteria and cause intestinal infection. (A) Non-motile 
probiotic bacteria (VSL#3) present at higher cell density compared to pathogen (S. 
typhimurium) effectively prevent S. typhimurium growth. The mucus interface is 
impenetrable to non-motile VSL#3, but hyper-motile S. typhimurium preferentially 
colonize the mucus layer. The escape mechanism is flagella dependent and enhance the 
infection ability of S. typhimurium. The epithelial barrier and innate immune cells 
(Macrophages and Dendritic cells) are the first responders in the inflammatory responses 
to pathogenic infection. (B) Fluorescent confocal microscope images showing epithelial 
cell adhesion molecule-1 localization (Red, arrow), S. typhimurium distribution (Green, 
arrows), and Epithelial cell nuclei with mucus gel matrix (Blue, arrows). (C) Fluorescent 
confocal microscope image of all three channels overlaid showing S. typhimurium 






FUTURE APPLICATIONS AND CONCLUSION 
5.1 Development of a probiotic encapsulation and delivery vehicle using PSIM 
The scalable mucus extraction process established in this work can enable development of 
delivery vehicles for orally ingested therapies. The intrinsic properties of mucus make this 
biomaterial an ideal candidate for oral delivery. We hypothesize that the intact sol-gel 
transition of mucus will protect a therapeutic compound or live probiotic bacteria from the 
harsh acidic environment of the stomach. We tested this concept by adding a droplet of 
PSIM (20 mg/ml) at pH 7 on top of a droplet of 20 mM HEPES buffer at pH 4 (Figure 5.1). 
Fluorescently labeled (Cy5) Sambucus nigra agglutinin (SNA) lectins were mixed in the 
PSIM solution for fluorescence microscopic visualization. A distinct ring of PSIM was 
formed with the aggregated PSIM on the outside. No aggregation was observed in the 
center of the ring. Cy5 lectin stain was also localized in the aggregated region with slight 
diffusion of possibly unbound lectin towards the center of the ring. This test indicates a 
feasibility of PSIM bead formation with an aggregated shell that forms a protective barrier 
against gastric acid and the desired therapeutic in the core of the bead (Figure 5.2A). We 
have demonstrated previously that PSIM is a solution at pH 7 but formed a gel at pH 4 and 
undergoes spontaneous sol-gel transition with change in the pH (Figure 5.2B). This 
property will be ideal for release of the encapsulated therapeutics in the neutral pH 
conditions present in the small and large intestines. To demonstrate the encapsulation, 
green, fluorescent polystyrene microbeads were mixed in PSIM (20 mg/ml) at pH 7. The 
mixture was gently pipetted into a bath containing 20 mM HEPES buffer at pH 4 forming 
a cross-linked spherical bead (Figure 5.2C). Fluorescent confocal microscopy showed 
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embedded GFP expressing polystyrene microbeads in the matrix of the PSIM beads (Figure 
5.2D). This concept can be applied for encapsulation, gastric protection, and delivery of 
probiotic bacteria to the intestines. 
To streamline this process a microfluidic platform can be utilized that will enable 
encapsulation of the probiotic bacteria in PSIM (pH 7) using a flow focusing channel 
containing a buffer solution at pH 4 (Figure 5.2E). After the beads are formed, they will 
pass through another flow focusing junction where the beads will be exposed to a buffer 
solution at pH 2. The beads can be collected while immersed in the pH 2 buffer solution. 
Lyophilization of the beads can be tested for long-term storage of the encapsulated 
probiotic bacteria. Further validation will be required to test if the beads are actually 
forming core-shell regions. Furthermore, the viability of the encapsulated probiotic 
bacteria can be tested by solubilizing the beads in a buffer solution at pH7. PSIM can be 
expected for good tolerance in the intestines since the mucin macromolecules are highly 
abundant in the lumen. To be clinically applicable, PSIM should be tested for presence of 
any endotoxins and other immunostimulatory antigens. Information on the exact 





Figure 5.1 PSIM ring formation in low pH. Microscopic images of PSIM droplet (pH 7) 
interacting with a 20 mM HEPES buffer droplet (pH 4) and forming a ring with aggregated 






Figure 5.2 Conceptual design of core-shell particles of PSIM for probiotic 
encapsulation. (A) Schematic of the hypothesized PSIM beads that encapsulate probiotic 
bacteria in the core, protects the bacteria from gastric acid and releases the bacteria in the 
neutral environment of the intestines by reversible gel to sol transition. (B) Demonstration 
of sol (pH 7) to gel (pH 4) transition of PSIM (80 mg/ml) compared to commercially 
available porcine gastric mucin (PGM) that does not undergo sol-gel transition in response 
to pH change. (C) PSIM bead formation by gently pipetting 10 μl of PSIM (pH 7) into a 
bath of 20 mM HEPES buffer (pH 4). (D) GFP expressing polystyrene beads (1 μm size) 
embedded in Cy5 lectin stained PSIM gel matrix. (E) Proposed microfluidic device for 
streamlining probiotic encapsulation, uniform sized bead formation, and collection of 




5.2 Creation of a two-layer mucus barrier relevant to the large intestine mucus 
barrier 
Large intestines are the biggest reservoir of bacteria in the human body. The mucus layer 
protects underlying tissue from coming in direct with the bacteria. The most intriguing 
feature of the mucus layer in the large intestine is the structural organization into a two-
layer system. The inner layer is tightly bound to the epithelium and is devoid of bacteria. 
The outer layer is loosely attached and is colonized by commensal bacteria. The exact 
mechanisms of how this structural layering is achieved in vivo are still being discovered. 
Consequently, it has been challenging to recreate the two-layer mucus barrier of the large 
intestine in vitro. Development of an in vitro model that mimics this essential feature of a 
healthy mucus barrier can provide significant insights into the factors that can lead to 
pathological conditions of large intestines. We have demonstrated before that PSIM forms 
structurally stable layers on top of transwell membranes in Chapter 2. The structure of the 
PSIM can be controlled by changing PSIM concentration, addition of multivalent cations, 
and changing pH. Since the pH in the intestines is maintained close to neutral, we utilized 
the change in PSIM concentration and Ca2+ ion concentration to create multiple layers with 
structural differences. Since the inner mucus layer is known to be more cross-linked and 
impenetrable to bacteria, we used a combination of high PSIM concentration (100 mg/ml) 
and high Ca2+ concentration (100 mM) to create this layer (Figure 5.3A). A 50 µL solution 
of PSIM in 20 mM HEPES buffer was added to the apical compartment of a transwell 
insert (3 µm pore size) and 100 mM CaCl2 solution in 20mM HEPES buffer was added to 
the basolateral compartment of a 24 well plate. After incubation at 37oC in a humidified 
incubator for 12 hours, 100 µL solution of PSIM (20 mg/ml) was added on top of the 
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preformed mucus layer. After incubation at 37oC in a humidified incubator for 12 hours, 
the transwell membranes were carefully separated from the inserts and immersed in 10 % 
Formalin solution for 30 minutes. The fixed mucus layers were embedded in optimum 
cutting temperature (OCT) matrix and cryo-frozen by immersing in liquid Nitrogen. The 
frozen samples were sectioned into 20 µm thick slices using a cryostat. Fluorescently 
labeled (Cy5) Sambucus nigra agglutinin (SNA) lectins were mixed in the PSIM solution 
prior to gel formation to facilitate imaging after cryo-sectioning. The combination of high 
PSIM concentration (100 mg/ml) and gradient of Ca2+ ions from the basolateral 
compartment lead to formation of highly cross-linked mucus gel layer (Figure 5.3A). The 
gel layer was structurally stable and could be visualized microscopically by fluorescent 
microscopy. By adding PSIM solution at low concentration (20 mg/ml) on top of the first 
layer formed a structurally distinct outer mucus layer (Figure 5.3B). Fluorescent 
microscopy showed a clear interface between the two layers along with difference in the 
structure of both layers. The inner layer showed large areas of dense aggregates identified 
by bright fluorescence indicating higher density and cross-linking. The outer layer had 
branched structure and no bright fluorescent aggregates indicating the absence of Ca2+ 
induced crosslinking and therefore a loose structure. The results show that the two-layer 
structure of mucus barrier present in the large intestine can be captured by using PSIM.  
Several challenges remain to make this system more physiological. The transwell platform 
does not allow the reduction in the height of the mucus layer formed. The viscoelastic 
properties and height of the inner and outer mucus layer needs to be tuned to match the in 
vivo properties of the mucus layers. This can be done by 1. Systematic testing of PSIM and 
Ca2+ concentrations, 2. Using methods like Particle tracking microrheology to measure the 
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viscoelastic properties of the gel layers formed, and 3. Creating tools to precisely control 
the thickness of the gel layers formed while still allowing the apical and basolateral 





Figure 5.3 Two-layer mucus barrier formation using PSIM. (A) Schematic of the inner 
layer formation by using high concentration of PSIM in the apical compartment and high 
concentration of Ca2+ ions in the basolateral compartment (Left). After incubation, a 
structurally stable mucus gel layer formed (Middle) which was visualized using fluorescent 
microscopy (Right). (B) Schematic of the outer layer formation by using low concentration 
of PSIM on top of the preformed inner layer in the apical compartment and HEPES buffer 
solution without Ca2+ ions in the basolateral compartment (Left). After incubation, 
structurally stable mucus gel layers formed (Middle) which were visualized using 







5.3 Microfluidic platform for dynamic mucus barrier formation using PSIM 
The mucus lining along the gastrointestinal tract is the outermost and largest interface in 
the body that protects the epithelium, regulates the selective transport of nutrients, and 
maintains symbiosis in presence of microbes (Figure 5.4). Goblet cells constitute about 4-
12% of epithelium in the small intestine and up to 20% in the large intestine, which 
correlates with the properties and height of the mucus barrier. In human intestines, the turn-
over rate of the entire mucus layer is close to 1 hour meaning that the mucus layer is 
essentially flowing at a very low rate. The secreted mucin biopolymers regulate barrier 
function via in situ biochemical and biophysical interactions with the luminal content that 
periodically fluctuates. Mimicking the mucus layer that is constantly replenishing and 
dynamically responsive to changes in surrounding environment (pH and ionic 
concentration) has not been realized in most commonly used in vitro models of human 
intestines. In vitro mucus barrier model that replenishes continually and is responsive to 
luminal content can serve as an enabling tool for understanding the interactions and 
transport of orally administrated drug compounds as well as bacteria across the protective 
mucus barrier in vivo. 
 
To achieve this a simple microfluidic design was developed that enables flow of luminal 
content and PSIM in parallel. The microfluidic design was prepared using Adobe Illustrator 
software. A single microfluidic channel with Y-shaped inlets and outlets was printed on a 
250 μm thick poly-dimethyl siloxane (PDMS) sheet using Graphtec plotter cutter. The 
PDMS sheet with the channel was bound onto a glass slide and covered with a thick PDMS 
sheet using oxygen plasma treatment for 2 minutes and a platform with multiple channels 
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on a single platform was created (Figure 5.5A). The channel layer was covered on top with 
a 3 mm thick PDMS layer with the inlet and outlet ports punched prior to oxygen plasma 
bonding for 2 minutes. All surfaces must be kept clean by washing in 70 % Ethanol and 
allowing the ethanol to air dry without touching the surface. The syringes containing PSIM 
or buffer solution were connected to the inlet ports using polypropylene tubing with 1 mm 
inner diameter. The flow was controlled using Harvard apparatus syringe pumps. The 
channels were filled with 20 mM HEPES buffer at pH 7 before connecting the inlet and 
outlet tubing to prevent air bubble formation. The exclusive presence of laminal flow 
profile in microfluidic devices prevents mixing and enables the study of diffusion across 
the interface between the two phases (Figure 5.5B). The device was tested by flowing a 
solution of food coloring dyes (blue and red) at a flow rate of 10 μl/min. A distinct interface 
was formed at the center of the main flow channel. 
 
To demonstrate this concept with luminal content and mucus, PSIM in 20 mM HEPES 
buffer at a physiological concentration (20 mg/ml) and pH 7 was flown from one inlet and 
luminal content (20 mM HEPES buffer) with changing Ca2+ concentrations was flown 
from the other at a flow rate of 10 μl/min. We hypothesized that at the interface where the 
luminal content came in direct contact with PSIM, a diffusive barrier would form due to 
Ca2+ induced aggregation and cross-linking of mucus. Indeed, a visible barrier formed that 
changed in real time in response to Ca2+ concentration in the luminal content (Figure 5.6A). 
The thickness of the mucus gel layer increased by increasing the Ca2+ concentration in the 
luminal compartment (Figure 5.6B). At 5mM Ca2+, mucus gel layer did not form in the 
entire channel. Increasing the Ca2+ concentration to 25 mM significantly increased the 
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thickness of the layer. Further increase in the Ca2+ concentration to 100 mM caused a 3-
fold increase in the gel layer thickness compared to 25 mM Ca2+. Increasing gel layer 
thickness caused reduction in the diffusion of FITC dextran (20 kDa) (Figure 5.6C). At 5 
mM Ca2+ FITC dextran diffused across the interface and there was no difference in the 
GFP intensity in the luminal half and the mucus layer. At 25 mM and 100 mM Ca2+ a 
significant reduction in GFP intensity was measured in the mucus layer suggesting that the 
Ca2+ induced cross-linking of mucus at the interface acts as a barrier for molecular 
diffusion. In our preliminary testing, mucus aggregates also formed in the presence of most 
physiologically relevant and multivalent cationic species like Mg2+, Zn2+, Fe2+, and Fe3+. 
Most of these cations including calcium are present in foods and supplements ingested by 
humans on a regular basis. Therefore, the role these cations in the barrier function and 
nutrient absorption across the intestinal mucus barrier can be systematically explored using 
the microfluidic platform. The ease of imaging will enable systematic characterization of 
transport behavior of fluorescently labelled carbohydrates, amino acids, lipids, food grade 
nanoparticles, and live bacteria across the mucus barrier while changing pH and ionic 
concentrations.  
 
Currently, the microfluidic device requires both the luminal content flow and PSIM to flow 
at equal flow velocity for the interface to form at the center of the device. Setting the flow 
rate at 10 10 μl/min in both the flow streams also ensured proper clearance of the device 
for operation until 1 hour. Under the current operating parameters, the flow velocity is two 
orders of magnitude higher than the physiological replenishing rate of mucus (hourly 
turnover). However, reducing the flow rate close to the physiological range caused 
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accumulation of aggregates, disruption of the gel layer interface and clogging of the device. 
Also. It may be ideal to have a stable static mucus barrier and flowing luminal content 
which will enable consistent quantification of diffusion across the mucus layer. However, 
stopping the mucus flow also leads to accumulation of aggregates, disruption of the gel 
layer interface and clogging of the device. One solution for this problem is to optimize the 
mucus flow rate as close to physiological as possible without clogging the device for at 
least 30 minutes. Matching the flow rate of luminal content with the optimized mucus flow 
rate will ensure a uniform interface formation that will also enable consistent measurement 
of diffusion across the gel layer formed at the interface. Another solution for this problem 
is to quantify the diffusion exclusively in the region of the gel interface. Since the gel 
interface once formed remains static irrespective of the flow rates of the luminal content or 
the PSIM. This strategy is more feasible for particle of micrometer scale and bacteria but 








Figure 5.4 Luminal environment of the intestines is highly complex and dynamically 
evolving. Schematic showing the complex environment in the lumen of the intestinal tract 
including endogenously secreted gastric acid, bile salts, enzymes, and the resident 
microbiota. The lumen is also exposed to exogenous factors such as dietary molecules and 
pathogenic bacteria. The continuous secretion of the mucus and peristaltic movement of 
the luminal contents help in physically protecting the underlying tissue and clearance of 






Figure 5.5 Dynamically responsive mucus barrier in a microfluidic platform. (A) 
Schematic of the microfluidic device fabrication process. (B) Schematic of the conceptual 
flow regimes in the 2-inlet microfluidic device. (C) Digital images of the microfluidic 
device in operation, microscopic image of the flow channels and food coloring dye blue 




Figure 5.6 Regulation of molecular diffusion via PSIM gel formation at the lumen-
mucus interface. (A) Microscopic images of Ca2+ dependent PSIM gel interface forming 
in the central microchannel. (B) Thickness of the gel interface increases with increasing 
Ca2+ concentration. (C) Diffusion of FITC dextran (20 kDa) dye is reduced with increasing 





5.4 ‘Intestine mucosal barrier on a chip’ for real time host-microbe interaction 
To mimic intestinal physiology, two microfluidic designs were developed to combine a 
flow channel for luminal content, a flow channel for replenishing mucus layer and 
epithelial cell layer (Figure 5.7). This way bacteria can be cocultured with epithelial cell 
surface in presence or absence of mucus layer. Continuous removal of culture medium will 
prevent bacterial overgrowth. Due to the planar design of the microfluidic platform, 
interactions of bacteria with mucus gel and epithelial cells can be captured in real time.  
The devices were designed to specifically include 1. Resident immune cells embedded in 
extracellular matrix to mimic the innate immune responses, 2. Endothelial cell layer with 
a separate flow channel for capturing transmigration of effector cells into the extracellular 
matrix following a chemokine gradient. The devices were developed using a simple and 
cost-effective strategy that eliminated the use of microfabrication related instruments and 
cost involved.   
  
The microfluidic design was prepared using Adobe Illustrator software. A single 
microfluidic channel with Y-shaped inlets and outlets was printed on a 500 μm thick poly-
dimethyl siloxane (PDMS) sheet using Graphtec plotter cutter. The PDMS sheet with the 
channel was bound onto a glass slide and covered with a thick PDMS sheet using oxygen 
plasma treatment for 2 minutes and a platform with two devices on a single glass slide was 
created (Figure 5.8A). In a biosafety cabinet, the PDMS pieces cut out from the sheet were 
placed back in their position except the rectangular piece designated for collagen gel layer 
formation. Rat tail collagen (Type 1) solution (8 mg/ml) and 10x concentrated cell culture 
medium (w/ Phenol red) were placed on ice. The collagen solution and the 10x medium 
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were mixed in a proportion of 9-parts collagen and 1-part 10x medium and mixed gently 
to prevent any air bubble formation while keep the solution on ice at all times. The mixed 
solution (25 μl) was gently pipetted in the vacant rectangular piece making sure that no air 
bubble form and the solution is in contact with all the corners. For embedding immune 
cells in the collagen gel, the immune cell pellet should be formed by centrifugation and 
then resuspended using the collagen-medium solution. Depending on the efficiency of 
mixing, the collagen-medium solution will start to turn opaque at room temperature in 5-
10 minutes indicating the collagen gel formation. To speed up the gel formation, the 
collagen-medium solution can be incubated in a humidified incubator at 37oC with constant 
monitoring of the gel. The gel should not be left for too long at room temperature or 37oC 
incubator as the dehydration of gel will affect the sealing of the collagen gel to the top 
PDMS and bottom glass surface. After gel formation, the PDMS pieces inserted in the main 
channels were gently removed (Figure 5.8B). This layer containing the collagen gel and 
the flow channel on the glass slide should not be taken out of the biosafety cabinet to 
maintain sterility and should not be exposed to plasma treatment. The channel layer was 
covered on top with a 3 mm thick PDMS layer with the inlet and outlet ports punched prior 
to oxygen plasma bonding for 2 minutes. While binding ensure the alignment of the inlet 
and outlet ports with the channels and are should be taken to not disturb the collagen gel 
layer. All surfaces must be kept clean by washing in 70 % Ethanol and allowing the ethanol 
to air dry without touching the surface inside a biosafety cabinet. For cell seeding and 
culture 200 μl pipet tips were inserted in the inlet and outlet ports and the medium level 
was maintained by gravity driven flow (Figure 5.8B). For flow experiments, the syringes 
containing cell suspensions, PSIM and cell culture medium solution were connected to the 
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inlet ports using polypropylene tubing with 1 mm inner diameter. The flow was controlled 
using Harvard apparatus syringe pumps. The channels were filled with cell culture medium 
before connecting the inlet and outlet tubing to prevent air bubble formation. 
 
To test the stability of the cell-free collagen layer (Figure 5.9A), gravity-driven flow was 
used to perfuse phosphate buffer solution (PBS) containing 1 µg/ml of FITC dextran (20 
kDa) and TRITC dextran (155 kDa). The devices were imaged over time for GFP and RFP 
fluorescence to quantify the rate of diffusion of these molecules across the collagen gel 
layer (Figure 5.9B). FITC dextran diffusion was significantly faster compared to TRITC 
dextran over time indicating that the rate of diffusion is size-dependent. Differences in the 
rate of diffusion of the two differently sized molecules also suggest that there is no leakage 
around the edges of the collagen gel. Additionally, the diffusion appeared to be uniform 
along the entire length of the collagen gel. FITC dextran (20 kDa) diffused across the entire 
width of the collagen gel reaching close to steady state in 4 hours suggesting that the cells 
can be embedded in the collagen gel since the nutrients can easily diffuse across the gel 
layer.  
 
Immune (THP-1) cells embedded in the collagen gel under static conditions remained 
viable for more than 7 days (Figure 5.10A). The cell culture medium was replaced every 
other day. Cell viability was confirmed by blue, fluorescent live cell tracker (Hoechst 
33342). Coculture of immune cells with live bacteria was tested by introducing red 
fluorescent protein (RFP) expressing E. coli Nissle 1917 strain in the luminal channel. 
 
123 
Fluorescence microscopy was used to track the growth of bacteria over time confirming 
the ability of real time imaging in the microfluidic platform (Figure 5.10B).  
 
To establish the epithelial cell layer, epithelial (HT-29) cells were seeded on one edge of 
the gel by seeding 105 cells per device, setting the device vertical so that suspended cells 
settle on the collagen gel surface and incubated at 37oC and 5% CO2 in a humidified 
incubator. Cell culture medium was changed daily, and coverage of the epithelia cells was 
confirmed by brightfield imaging (Figure 5.11A). Epithelial cells covered the entire surface 
of the collagen gel in 3-5 days. The cell layer was fixed by perfusing 10% Formalin solution 
and incubating at room temperature for 30 minutes. To confirm the formation of tight 
epithelial barrier, HT-29 cells were stained with EPCAM-1 (Red) and nuclei (Blue). The 
epithelial cells formed a 3D structure with well-defined epithelial cell junctions (Figure 
5.11B). To mimic the physiological complexity of intestines, PSIM gel layer was 
reconstituted in the main channel along with green fluorescent protein (GFP)-expressing 
bacteria suspended in cell culture medium (McCoy’s 5A) supplemented with 20 mM Ca2+. 
To demonstrate continuously replenishing luminal content, flow was maintained at 3 
μl/min. Calcium induced aggregation created a distinct separation between the epithelial 
cell layer and the GFP bacteria flowing across the luminal side (Figure 5.11C top). By 
stopping the flow, mucus barrier was disrupted that caused the bacteria to fill the entire 
channel and came in direct contact with the epithelial cells (Figure 5.11C bottom).  
 
Similarly, to establish endothelial cell layer after epithelial cell attachment, endothelial 
(HUVEC) were seeded on the other edge of the gel by seeding 105 cells per device, setting 
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the device vertical so that suspended cells settle on the collagen gel surface and incubated 
at 37oC and 5% CO2 in a humidified incubator. Collagen gel successfully created a partition 
between the top Y-inlet channel and the straight channel on the bottom (Figure 5.12A). 
Epithelial cells formed a uniform layer on the top edge of the collagen layer and expressed 
epithelial cell adhesion molecule - 1 (EPCAM-1) after 3 days of culture (Figure 5.12B). 
Endothelial cells formed an interconnected cell layer on the bottom edge of the collagen 
gel confirmed by platelet and endothelial cell adhesion molecule - 1 (PECAM-1) 
expression. Immune cells can be directly injected into the channel on endothelial side. 
Mucus and bacteria can be injected into the Y-shaped inlets. Cell viability and 
differentiation can be quantified using fluorescent confocal microscopy and flow 
cytometry.  
 
The microfluidic mucosal barrier model provides a high throughput platform to test 
hypothesis related to efficacy and immune compatibility of probiotics and therapeutics. 
Simple chip design allows for real time monitoring of multiple species of bacteria co-
cultured with human derived epithelial and endothelial cells. Continuously replenishing 
luminal content and the mucus gel layer can enhance the physiological relevance of this 
model. Additional work is needed to confirm the sealed epithelial cell layer formation. Cell 
seeding for epithelial, immune, and endothelial cells also needs to be adjusted to reflect the 
physiological structure of the intestines. Different methods will be required to quantify the 
permeability of the epithelial cell barrier such as dye-based methods or advance methods 
to measure trans-epithelial electrical resistance (TEER). We found that HT-29 cells start to 
form 3D aggregates after long-term culture. Other cell lines such as Caco-2 can be tested 
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for better results with cell coverage and forming a sealed epithelial barrier. Additionally, 
methods can be explored for covalent cross-linking of the collagen gel with the bottom 
glass slide and the top PDMS cover for preventing leakage on the edges for long-term 
studies. Also, immune cells showed limited migration in the collagen gel at the 
concentration of collagen tested. Therefore, further tuning the collagen gel to enable 
immune cell activity will enhance the functionality and applicability of this device. Since 
the thickness of the collagen cannot be reduced further due to technical reasons, more 
advanced methods can be tested to achieve vascularization of the collagen gel by 
endothelial cells. This will enable capturing the phenomena of immune cell trafficking 
from the immune cell channel to the site of epithelial cell injury in the microfluidic 
platform. The assembly of the microfluidic chip is such that the cells can be retrieved for 
downstream analysis including flow cytometry, DNA, RNA, and protein quantification. 
Secreted molecules such as cytokines and chemokines can be easily retrieved for 




Figure 5.7 Microfluidic platform to reconstitute the mucosal and immunological 
function of the intestines. (A) Schematic of the physiological structure and the cells 
present at the mucosal interface. Mucus layer, epithelial barrier and the cells of innate 
immune cells are in constant communication with the intestinal microbiota. (B) A 
microfluidic chip design to incorporate bacteria, mucus, epithelial, and immune cells in a 
physiological manner. (C) A microfluidic chip design that incorporates an additional 






Figure 5.8 Fabrication of the microfluidic platform containing the collagen gel for 
supporting epithelial cell layer and embedded immune cells. (A) Schematic of the steps 
involved in the fabrication of the microfluidic chip. (B) A key step in the fabrication 
process is the manual addition of the collagen solution, and careful removal of the thin 
PDMS piece from the central channel. The planar design enables real-time imaging of the 







Figure 5.9 Testing the stability of the collagen gel and quantifying diffusion across the 
gel layer. (A) Brightfield microscope image shows a stable collagen gel layer formed in 
the rectangular region. The luminal channel is accessible to inlet and outlet flow. (B) 
Fluorescent microscope images showing the diffusion of two different sizes of dextran 
molecules. The rate of molecular diffusion was quantified by measuring the fluorescence 






Figure 5.10 Testing viability of embedded immune cells and coculture with live 
bacteria. (A) Fluorescent microscope image of THP-1 cells embedded in the collagen and 
stained with blue live cell tracker. (B) RFP expressing E. coli Nissle 1917 cocultured with 
embedded THP-1 cells. Bacteria growth and interaction with the immune cells was 






Figure 5.11 Demonstrating epithelial and mucus layer formation and coculture with 
live bacteria. (A) Brightfield microscope image of the microfluidic device showing the 
HT-29 epithelial cell layer covering the entire surface of the collagen gel. (B) High 
magnification image shows 3D growth of epithelial cells and the fluorescent microscope 
image shows the formation of epithelial cell junctions (EPCAM-1). (C) Fluorescent 
microscope images show the maintenance of steady state by flowing the mucus layer and 
the luminal content at equal flow rate of 3 μl/min. Presence of 20 mM Ca2+ in the luminal 
content enable the formation of a distinct interface separating the bacteria (GFP S. 
typhimurium) and the mucus layer. The underlying epithelial layer (blue) is prevented from 
bacterial infection. Disrupting the flow of mucus caused infiltration of bacteria into the 






Figure 5.12 Demonstrating epithelial and endothelial layer formation in a single 
microfluidic device. (A) Brightfield microscope image showing the collagen gel 
separating the epithelial (Top) and the endothelial (Bottom) channels. (B) High 
magnification images showing the formation of uniform epithelial (HT-29) and endothelial 
(HUVEC) cell layers after three days of culture. Immunostaining of the fixed cells show 
that epithelial cells expressed EPCAM-1 (Red) and the endothelial cells expressed 






5.5 Incorporation of primary gut organoids and immune cells for ‘Personalized 
Medicine’ applications 
Primary stem cell-derived organoids contain all the different types of cells present in the 
epithelial cell layer in vivo including absorptive enterocytes, mucus secreting goblet cells, 
Paneth cells, enteroendocrine cells, and microfold cells. Presence of these cell types enable 
testing of specific hypotheses in vitro depending on the specialized function of the 
respective cell type. The discovery of stem cell marker Lgr5 and commercial technology 
development in the recent times have simplified the extraction of stem cells from freshly 
excised tissues and the growth of these stem cells into three-dimensional (3D) organoids 
(Figure 5.13A). These organoids are grown embedded in the extracellular matrix (ECM) 
like Matrigel and form an enclosed structure with the lumen on the inside of the 3D 
structure that is difficult to access for stimulation (Figure 5.13B). However, these organoids 
can be dissociated to into single cells and re-seeded in commonly used platforms including 
transwells, ECM derived scaffolds, and microfluidic platforms. This way in vivo like 
epithelial monolayers can be formed that are accessible on both apical and basolateral sides 
for drug discovery, studying transport or molecular secretion from the cells after 
stimulation. To develop personalized models, the methods for recreating the mucosal 
barrier presented in the thesis using immortal cell line for epithelial barrier can be easily 
replaced with the primary epithelial cells derived from stem cell organoids (Figure 5.13B). 
Additionally, the immortalized cell lines can be replaced by peripheral blood derived 
mononuclear cells (PBMCs). PBMCs constitute a diverse population of the immune cells 
that represent the effector cells during an immune response to immunomodulatory 
molecules or infectious agents like bacteria, viruses, fungi, and parasites present in the 
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lumen of the intestines. By donor matching the epithelial and immune cells in the in vitro 
platforms described in this thesis can serve as personalized models for real time testing of 
the efficacy and safety of probiotic bacteria and the fecal microbiota transplant (FMT) in 





Figure 5.13 Intestinal stem cell isolation and growth into 3D organoids. (A) Small 
intestines excised from transgenic mice expressing red fluorescent protein variant (DsRed-
Express) under the direction of the mouse doublecortin (Dcx) promoter using a commercial 
isolation kit and protocol (Stemcell Technologies Inc.). Cells are embedded in a dome of 
Matrigel matrix. (B) 3D buds start to originate from individual stem cells after 1 day of 
culture. After 7 days of culture crypt and villous structure form with a lumen at the center 
of the organoids that contain dead cell debris. (C) Schematic of a ‘single translational 




5.6 Overall conclusion 
In the first part of the thesis, a high throughput method to extract natural mucus was 
developed that will stimulate broad aspects of mucus barrier research. Using mucus 
extracted with this process, we have shown that the local ionic environment plays an 
important role in regulating the biophysical properties of the mucus barrier. Integration of 
the extracted mucus with an epithelial cell layer lead to the development of the mucosal 
barrier model of the intestines in vitro. Using the mucosal barrier model, we demonstrated 
the role of flagellar motility in promoting bacterial infection and inducing pro-
inflammatory cytokine and chemokine production from epithelial and immune cells. 
Mucosal barrier model was further used to elucidate that depending on the dosage, 
probiotics can be beneficial against pathogenic infection, but insufficient dosage and 
presence of mucus induce hypervirulence in S. typhimurium and higher inflammatory 
response. Finally, advanced applications of the mucus biomaterial in developing 
translational platforms ranging from therapeutic delivery to micro-physiological models 
using microfluidics have been described. The techniques presented here will help uncover 
the mechanisms behind the effects of environmental molecules on biophysical properties 
of mucus. The in vitro mucus barrier model is functional and can be tuned to match 
physiological thicknesses and densities like native mucus. We envision that these models 
will serve as high throughput tools for understanding the role of mucus barrier in nutrient 
absorption, host-microbiome interactions, and drug absorption. A better understanding of 
mucosal barriers and their interaction with the local environment has potential to improve 





   
Figure 2.S1. Quantification and removal of total DNA post PSIM extraction. Change 
in total DNA after DNAse treatment of PSIM at room temperature for 10 hours compared 





Figure 2.S2. Theoretical quantification of total mucus on the luminal surface of the 
pig intestines. Schematic representation of gross small intestinal (SI) morphology and 
microstructure showing the components that contribute to increase in the surface area of 
the small intestine. In the equation for mucus amount, π (Ro
2 –Ri
2) is the cross-sectional 
surface area of a hollow cylinder, and plicae circularis and villi structures increased the 
cross-sectional area by factors of 3 and 7.55, respectively. The theoretical amount of mucus 
per meter length was based on an outer radius (Ro) of 12.5 mm, an inner radius (Ri) of 





Figure 2.S3. Absorbance spectra of 2 % (w/v) PSIM in the pH range 2-7. Data was 





Figure 2.S4. Rheological data for the change in dynamic moduli (G՛ and G՛՛) of PSIM 
(2% w/v). The measurements were performed in the frequency range 1-68.3rad/s at 37oC 
(N = 3 PSI).  




Figure 2.S5. Gross image of PSIM compared to Porcine gastric mucin (Type II, Sigma 
Aldrich). The freeze-dried samples were solubilized in 20mM HEPES solution at a 






Figure 3.S1. Mucus layer thickness is concentration dependent. (A) Brightfield 
micrographs of histological sections with epithelial layer (black border arrows) and mucus 
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